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Preface 
The studies presented in this Thesis are based on a research project initiated in 1993 by the late 
Professor Knut Nygaard. His large interest and competence in colorectal cancer treatment was a great 
inspiration for the younger colleges. All patients admitted to Oslo University Hospital, Aker were 
prospectively included, and a comprehensive set of clinical and pathological data from the primary 
treatment and follow-up was registered and entered into a local database. Professor Nygaard saw the 
potential for quality assessment and clinical research based on these registrations. Professor Arild 
Nesbakken attended the department in 1995, and immediately became responsible for the registry. 
Since Professor Nygaard resigned in 1997, he has been responsible for the whole research project.   
In the early nineties, a standardised technique for rectal resection, total mesorectal excision (TME) as 
described by R. J. Heald, was introduced in our hospital and nationwide in Norway. TME has been 
one of the most important contributions to oncological surgery during the last 25 years, leading to 
decreased rates of local recurrence and improved survival1. Several studies on TME for rectal cancer, 
based on the research project which started in 1993, have been published, describing local recurrence 
rates and survival2, early complications3, and functional outcome – including neorectal function4, 
sexual- and bladder function5 and the long term consequences of anastomotic leakage6.  
The operative technique for treatment of colon cancer has been basically unchanged for decades. 
However, in recent years new attention has been given to the importance of lymph node removal for 
correct staging and improvement of oncological outcome, and to the importance of correct dissection 
in the mesocolic plane to secure free radial margins. Corresponding to the TME for rectal cancer, the 
concept of complete mesocolic excision (CME) for colon cancer has been introduced.  However, the 
surgical technique still varies between centres and individual surgeons, both in Norway and 
internationally.  
Ole H. Sjo was introduced to and engaged in the research project in 2003, and had a special focus on 
clinical research on colon cancer. A number of clinicopathological factors with prognostic impact 
were known at that time. Other factors were supposed to have prognostic impact, but reports were 
equivocal, and further studies were warranted. Our large, prospective and population based patient 
series was considered suitable for such studies, and the results are presented in this Thesis.  
A translational research program in cooperation with The Institute for Cancer Research, Oslo 
University Hospital, Radiumhospitalet and based on the same patient cohort, was started in 2005 in 
order to evaluate the prognostic and predictive impact of molecular genetic factors.   
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General introduction 
 
Epidemiology 
Incidence 
Cancer is a major health problem in the world, and colorectal cancer (CRC) is the third most common 
cancer and the fourth most frequent cause of cancer-related death worldwide. The incidence is highest 
in North America, Australia/New Zealand and Western Europe and lowest in Africa and Asia. More 
than a million new cases are diagnosed every year and approximately half of these patients will die 
from the disease within five years. The lifetime risk of developing colorectal cancer is 4-5% in the 
Western World. In Norway, the cumulative risk of developing colon cancer by the age of 75 years was 
3.0% for males and 2.7% for females7 during 2004-2008, and CRC is the second most frequent cancer 
after breast cancer in women,  the third most frequent after prostate and lung cancer in men, and the 
most common cancer for both genders together7. The incidence has doubled for both genders during 
the last 35 years. The rates are among the highest in the world, and for women  highest in Europe8. In 
the Nordic countries, Norway has the highest rates for both genders (Figure 1 and 2). Overall, the 
incidence in Norway over the last years seems to stabilise, at least for women7.  
 
 
Figure 1: Incidence for males in the Nordic countries 1972-2006, all ages                           
Source: (NORDCAN; http://www-dep.iarc.fr/nordcan/English/frame.asp) 
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Figure 2: Development of incidence in the Nordic countries 1972-2006, females 
 Source: (NORDCAN; http://www-dep.iarc.fr/nordcan/English/frame.asp) 
 
Survival 
Long term survival in colon cancer patients has improved over the last decades; from 1965 to 2007, 
the 5 year relative survival rates in Norway, adjusted for survival in the general population,  have 
increased from below 30% to approximately 60% for men and 65% for women9, paralleling the 
increased rates of incidence.  
Long term survival in colon cancer patients is strongly dependent on stage of disease at the time of 
diagnosis. For all stages, the relative risk of cancer associated mortality is highest during the first years 
after diagnosis and treatment, then stabilising after about five year (Figure 2). 
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Figure 3: 15 year relative survival in colon cancer patients for both genders, related to stage of 
disease at the time of diagnosis 9.  
 
Aetiology / genetics in colon cancer 
The present studies are made on adenocarcinomas, the most frequent histological type of colon cancer, 
which accounts for some 98% of all malignancies in the large bowel10. The majority of 
adenocarcinomas occur sporadically (75-85%)11, but 25-30% of the patients have a family history of 
cancer. In about 5% of the CRC patients, an inherited germline gene defect is confirmed. The study of 
these inherited defects has yielded insights into the genetics of sporadic colorectal carcinogenesis. 
Hereditary CRC syndromes 
The most common of these syndromes is the Lynch Syndrome, also known as Hereditary Non 
Polyposis Colon Cancer (HNPCC), which is an autosomal dominant disorder and accounts for 1-6% 
of all malignancies of the colon12. This syndrome is characterised by early onset of CRC (mean age < 
45 years), with tumours predominantly located in the right colon (70%)12, and often associated with 
synchronous (18%) or metachronous (24%) tumours. In Type I, the only affected organ is the large 
bowel; in Type II, there are additional extra colonic tumours13. The syndrome is caused by mutation in 
one of the five human mismatch repair (MMR) genes, essential in repairing the nucleotide repeats 
(microsatellites) that are prone to slippage during replication14. The second most frequent inherited 
syndrome, the Familial Adenomatous Polyposis syndrome (FAP), accounts for less than 1% of all 
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CRC15. From early adolescence and onwards, patients with this condition develop hundreds to 
thousands of polyps in the colon and rectum. There are several clinical variations of FAP, such as 
Gardner’s syndrome16, Turcot’s syndrome17 and the attenuated form of FAP18. FAP is caused by 
germline mutations in the tumour suppressor gene APC (adenomatous polyposis coli), also found to be 
frequently mutated in sporadic colorectal cancers. Other inherited CRC syndromes are rare and 
includes the Peutz-Jegher’s syndrome with mucocutaneous pigmentation and gastrointestinal 
hamartomas, the juvenile polyposis syndrome  with multiple hamartomatous polyps spread throughout 
the gastrointestinal tract, and Cowden’s disease with multiple hamartomatous polyps, neurologic and 
dermatologic symptoms12. 
Colorectal polyps  
The two main histological types of polyps in the colorectal mucosa are hyperplastic and adenomatous 
polyps. Carcinogenesis starting in hyperplastic polyps develops through serrated adenomas, and is 
suggested to be caused by microsatellite instability19, 20. This link to serrated adenomas may represent 
a carcinogenetic pathway largely independent of the adenoma-carcinoma sequence19. Risk factors are 
polyp size (>1 cm), multiple polyps (>20), family history of hyperplastic polyposis or CRC 21  
Most colon carcinomas develop from adenomas, which are separated into three histologially different 
types: tubular (75%), villous (10%) and tubulovillous (15%). Increased size, grade of dysplasia and 
villous structure is associated with increased risk of malignancy. Removal of adenomas in the colon 
and rectum decreases this risk of developing CRC22, 23. The transformation of adenomas to invasive 
cancer involves a wide spectre of genetic events including alterations of oncogenes, tumour 
suppressor- and mismatch repair genes24-26. 
 
The adenoma-carcinoma sequence / sporadic colorectal cancer 
A number of genetic and epigenetic changes affecting genes controlling cell proliferation and/or cell 
death trigger the development of carcinoma27 . Most CRCs arise sporadically from adenomatous 
polyps. The evolvement of carcinomas through different histopathological steps was suggested in 
197428, and some years later Vogelstein et al24 described genetic alterations in several genes 
accompanying this stepwise progression from a benign adenoma to a malignant carcinoma. This has 
been named the adenoma-carcinoma sequence and include mutations in the Adenomatous polyposis 
coli (APC), Kirsten-ras (K-ras) and TP53 genes amongst others29. Mutations in the APC gene,  which 
cause FAP if mutations are inherited, is one of the most frequently mutated genes in CRC and an early 
event in development of CRC30. K-ras mutations are also observed as early events25, 31, whereas 
mutations in the tumour suppressor gene TP53 is considered to be a relatively late event in colorectal 
carcinogenesis25, 32. However, many other genes are involved in the development of CRC, causing 
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changes in the chromosomal composition, instabilities in microsatellites or epigenetic changes that 
may induce malignant transformation with different patterns of proliferation, invasion and 
metastasis33-37.  
The knowledge of aberrant genes causing instability of the genome38, suggests at least two different 
main genetic pathways in the development of CRC39, the chromosomal instability (CIN) and 
microsatellite instability (MSI) pathways.  
Chromosomal instability   
The expression of a mutator phenotype in human cancers as an early step in tumour progression has 
been described27, 40. This is known as the chromosomal instable phenotype, and these cells typically 
display numerous chromosomal aberrations. The cause for this genetic instability still remains 
unknown, but changes in genes that are responsible for normal chromosomal number and integrity 
during cell division have been suggested as initiating events.  
Microsatellite instability  
Nucleotide repeats (microsatellites) numerous and distributed throughout the entire DNA sequence. 
They are prone to slippage during replication14, and functional mismatch repair (MMR) genes are 
essential for these aberrations to be repaired. 
The five MMR genes described above encode for most proteins of the MMR system, phylogenetically 
a highly conserved system and present across species. Mutations or methylation of MMR genes 
inactivate their function and give rise to uncorrected defects in the nucleotide repeats and subsequent 
MSI. Characteristically, MSI tumours are bulky and most commonly occur in the proximal colon. 
They have cells that are diploid, are histologically poorly differentiated, and of the mucinous type41. 
MSI tumours often present Crohn-like lymphocytic infiltrates42; the frequency of lymph node and 
distant metastases are lower than in CIN tumours43. 
Epigenetic changes 
Epigenetic changes are chemical modifications of DNA resulting in changes in gene expression. The 
main epigenetic modifier is methylation of cytosine located within the dinucleotide CpG44, 45, and CpG 
sites are widely and unsymmetrically distributed in the genome. When CpG islands are located in the 
promoter region of a gene it will result in transcriptional silencing of the gene expression. The 
methylation of multiple CpG islands, defined as CpG island methylator phenotype (CIMP), seems to 
be an event in about half of all sporadic CRCs46, and MSI tumours are often caused by epigenetic 
silencing of the DNA mismatch repair gene MLH1 47. Aberrant methylation linked to MSI is described 
as a third pathway of tumour suppressor gene inactivation in carcinogenesis48-50.  
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Figure 4: Distribution of chromosomal instability, microsatellite instability and CpG island 
methylator phenotypes in colorectal cancers51    All numbers are percentages of the overall number 
of patients. The subset of CRC displaying no genomic instability might be smaller than shown here 
(‘triple negative’) as flow-cytometry used to identify CIN is relatively insensitive. A proportion of 
these cancers might display minor chromosomal abnormalities. It is likely that many would become 
overtly CIN+, but changes in CIMP status over time cannot be ruled out at present. 
TP53 tumour suppressor gene 
The TP53 tumour suppressor gene is located at chromosome 17p, where allelic deletions are 
recognised to be involved in colorectal carcinogenesis24.  
TP53 encodes a tumour suppressor with multifaceted functions in the maintenance of genomic 
stability, regulation of the cell cycle and apoptosis52. Mutations in TP53 are typically found in CIN 
tumours, and are reported in approximately 50% of all colorectal carcinomas53, 54. Most mutations 
occur in the DNA binding domain, encoded by exons 5 to 853, 55. The incidence of TP53 mutations is 
highest in the distal colon56-58 
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Staging of colon cancer 
The Tumour Node Metastasis (TNM) staging system of the American Joint Committee on Cancer 
(AJCC)59, 60 and the International Union Against Cancer (UICC) is the international 
clinicopathological staging system for colorectal cancer. It is based on three components of the 
anatomic extent of the disease: T for the local extent of the primary tumour, N for the extent of 
regional lymph node metastases and M for the absence or presence of metastases to other 
regions/organs. The TNM classification system has been revised several times since the first edition in 
1982, and three revisions have been published since our database was established in 1993.  
 
Table 1: The TNM staging system of the AJCC/UICC for colorectal cancer; Comparison of the 
4th, 6th and 7th editions. 
Primary tumour (T)                 
4th edition  
61, 62      
6th  edition  
63, 64 
7th edition   
59, 65 
               Definition 
TX TX TX Primary tumour cannot be assessed   
T0 T0 T0 No evidence of primary tumour 
Tis Tis Tis Carcinoma in situ; intraepithelial or invasion of lamina propria     
T1 T1 T1 Tumour invades submucosa                                                        
T2 T2 T2 Tumour invades muscularis propria 
T3 T3 T3 Tumour invades through the muscularis propria into 
pericolorectal tissues                                   
T4 T4 T4a Tumour penetrates the visceral peritoneum 
T4 T4 T4b               Tumour invades or is adherent to other organs or structures 
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Regional Lymph Nodes (N)                                                                            
4th edition 6th edition 7th edition               Definition 
NX NX NX Lymph nodes cannot be assessed                                                      
N0 N0 N0 No regional lymph node metastasis 
N1 N1                       
N1a 
Metastasis in 1 regional lymph node                                           
N1 N1 N1b Metastases in 2 to 3 regional lymph nodes  
Not 
defined 
Not defined                       
N1c 
Tumour deposit(s) in the subserosa, or nonperitonealised 
pericolic or perirectal  tissues without regional lymph node 
metastasis                                                                                          
N2 N2 N2a Metastases in 4 to 6 regional lymph nodes    
N2 N2 N2b Metastases in 7 or more regional lymph nodes 
N3 Not defined Not defined Metastases to nodes along the ileocolic, right, middle, left or 
inferior mesenteric artery, and/or apical lymph node as described 
by the surgeon 
  
 
Distant metastasis  
4th edition 6th edition 7th edition               Definition 
MX MX MX Distant metastases cannot be assessed 
M0 M0 M0 No distant metastasis                                                                     
M1 M1 M1a Metastasis to single organ or site (e.g. liver, lung, ovary, non-
regional/distant lymph node)   
M1 M1 M1b Metastases to more than one organ/site or to the peritoneum 
                                                                                                                     
There are different prefixes used to indicate the basis of information used for classification: 
m = multiple primary tumours on primary site                                         
y = classification after neoadjuvant radio- and/or chemotherapy                                                               
r = recurrent tumour following a disease free interval                                                                                
c = classification based on clinical and radiological assessment                                                                
p = classification based on pathological evaluation                                                                            
a = classification at autopsy  
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The initial staging based on clinical information (cTNM) is essential for planning of treatment. 
Normally this includes endoscopy with biopsy of the primary tumour and CT scan of the chest and 
abdomen/pelvis.  
After surgical removal of the tumour - and metastases if necessary - a pathological examination will 
establish whether nodal or distal metastases are present. This staging is considered the most accurate 
and reliable (pTNM). 
The Dukes staging system, originally intended  for rectal cancer only66 but subsequently modified and 
made applicable to colon cancer67, was formerly in common use. This system is now often replaced by 
the more differentiated TNM staging system based on combinations of the TNM stages listed in Table 
1.  
The main purpose of staging is to stratify patients according to prognosis, with possible implications 
for adjuvant treatment and follow-up. Table 2 compares the (p)TNM and Dukes classification systems. 
 
Table 2: TNM staging system (sixth edition) compared with Dukes’ staging system 
 
TNM stage  T  N  M  Dukes 
0   Tis  N0  M0  A              
I   T1 – T2 N0  M0  A           
IIa   T3  N0  M0  B                                        
IIb   T4  N0  M0  B                                                 
IIIa   T1-T2  N1  M0  C                                          
IIIb   T3-T4  N1  M0  C        
IIIc   Any T  N2  M0  C                                        
IV   Any T  Any N  M1  D                                        
 
Basically, prognosis worsens with advancing stage. For clinical purposes, the subdivision of TNM 
stages II-IV (6th and 7th edition) is rarely practised in Norway. 
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Peritoneal carcinomatosis (PC)  
PC refers to the complex sequence of events by which tumour cells disseminate from their primary 
organ of origin to establish independent metastatic deposits on the visceral and parietal peritoneal 
lining of the abdominal cavity68. Distant dissemination may occur through several mechanisms. First, 
malignant cells may invade bowel wall veins and spread haematogenously to distant organs; second, 
through lymphatic vessels to regional and distant lymph nodes; third, when the serosal surface is 
involved, directly from the primary tumour to adjacent and distant peritoneal surfaces.  
The peritoneal metastatic cascade 
A complex sequence of events, described as ‘the peritoneal metastatic cascade’, characterises the 
development of PC69. The first step is the dissemination of free tumour cells to the abdominal cavity. 
Cells may also be liberated by tumour perforation, either spontaneously or inadvertently during 
surgery. Furthermore, tumour cells may be seeded from transected lymphatic- and blood vessels 
during surgery. The second step is the adhesion of liberated tumour cells to the innermost layer of the 
peritoneum, the mesothelium. Several adhesions molecules have been implicated in this process69. 
Tumour cells then penetrate the mesothelial monolayer and its basement membrane with subsequent 
invasion of the underlying connective tissue, tumour proliferation and the establishment of discrete 
metastatic tumour deposits. Finally, angiogenesis is induced to sustain tumour proliferation and enable 
further metastatic growth.     
Clinical features of PC 
The natural history of CRC patients presenting with PC at diagnosis is sparsely documented and based 
on data from selected series. The incidence of PC at the time of diagnosis is 7-10%70, 71. In recurrent 
disease, about 25% have PC71, 72 and 40% to 80% of those who die of the disease will have PC73.  
Imaging to detect PC is difficult as signs on CT scan can be subtle in early stages with limited tumour 
load and absence of ascites. In recent years, positron emission tomography (PET) has gained favour in 
assessing metastatic disease, but lesion less than 1 cm are difficult to detect74. In the majority of cases, 
the diagnosis is established at operation. 
The extent and distribution of PC can be described according to different scoring and staging 
systems69. The Peritoneal Cancer Index is widely used and includes assessment of small bowel 
involvement, which is an important selection criterion for operative treatment.  
Genetic changes in patients with PC have been investigated, and PC seems to be associated with CIN 
tumours, including mutation(s) in the TP53 gene.  
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Treatment  
Surgical treatment 
Surgical treatment of colon cancer depends on the extent of the disease at the time of diagnosis, and 
staging is essential when planning the operation. Preoperative work-up includes endoscopy, CT scans 
of the chest and abdomen/pelvis and in some cases PET-CT if distant metastases are suspected. 
Following staging, two possible situations may arise with different implications for surgical strategy – 
emergencies excluded. 
I. Colon cancer without distant metastases 
In this situation, surgery is performed with curative intent. The primary tumour should be removed 
with free resection margins including the mesocolic lymphovascular pedicle to the tumour bearing 
bowel segment. Precautions should be made to avoid intra-operative dissemination of tumour cells. 
Extent of bowel resection  
For oncological reasons, a free resection margin along the bowel wall of at least 5 cm at both sides of 
the tumour is necessary; however, several authors advocate a resection margin of 10 cm75-77.  
A free radial (circumferential) resection margin around the tumour and the mesentery is essential and 
is secured by an accurate dissection following the anatomical retroperitoneal plane75, 78. This technique 
is described as complete mesocolic excision (CME) by Hohenberger et al.75, 79, and improved local 
recurrence rates and cancer specific survival at five years have been reported. Adherence to the CME 
technique also resulted in reduced rates of involved resection margins and improved OS in the study 
by Bokey et al.78, and increased distance between the tumor and the high vascular tie, the length of 
large bowel and the area of mesentery80 
In approximately 5-10% of cases, the tumour is adherent to, or infiltrates adjacent organs/structures, 
either because of true tissue invasion or inflammatory adherence. Intra-operatively, tumour infiltration 
and inflammatory adherence cannot be reliably discerned, and the resection should be extended to 
include the infiltrated part of the neighbour organ/structure to secure a potentially curative operation76, 
77. Perforation of the bowel is to be avoided, as it is associated with poor prognosis81, 82 
It is mandatory to secure an adequate blood circulation the bowel ends planned for anastomosis (or 
stoma). The remaining circulation after the oncological necessary lymphovascular dissection (see 
below) decides how much of the colon to be removed. By right sided cancer a right hemicolectomy is 
required; by cancer in the descending colon a left hemicolectomy; by cancer in the sigmoid a resection 
of the sigmoid or left hemicolectomy is necessary, depending on the circulation. Tumours in the 
flexures are treated with extended hemicolectomies or a subtotal colectomy. Tumours in the transverse 
20 
 
colon are treated with resection of the transverse colon including both flexures or by subtotal 
colectomy. By synchronous cancers (i.e. two or more tumours simultaneously), a subtotal colectomy is 
warranted in most cases.  
Extent of lymph node dissection 
Regional lymph nodes may contain tumour cells as ITC, MM or ordinary metastases. Removal of all 
LN containing tumour cells is mandatory to obtain cure. Moreover, correct pN staging requires 
dissection of a certain number of lymph nodes.  
The regional lymph nodes are divided into three groups according to their localisation, and the 
nomenclature is different in Japan / the western world: N1 / paracolic or epiploic, N2 / intermediate 
nodes, and N3 / central or apical nodes (Figure 5). N1 denotes the nodes close to the bowel wall; N2 
nodes are situated along the main vessels (i.e. the ileocolic, the middle colic, the left colic and the 
superior rectal arteries and veins) and N3 are the central nodes at the origin of the main vessels 
(superior mesenteric vessels and inferior mesenteric artery). 
This classification of node stations parallels the classification of lymph node dissection as D1- D3. 
Thus, D1 dissection includes the N1 nodes, D2 the N2 nodes and D3 includes dissection and removal 
of the central N3 nodes (Figure 6). 
 
 
Figure 5: Regional lymph node groups (N1, N2 and N3) in relation to bowel wall 
For right sided colon cancer, a D3 dissection is widely recommended; for tumours in the transverse or 
left colon, at least a D2 dissection should be performed. It is a matter of debate whether a D3 
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dissection is necessary in this situation, but metastases to central lymph nodes (N3) in absence of 
distant metastases have been reported in 2-4% of patients83-85. These are patients who could be cured 
by a D3 dissection; following a D2 dissection, however, they might have a locoregional recurrence. 
Some authors therefore recommend D3 dissection also for left sided tumours79, 86, 87. 
Hohenberger also recommends removal of nodes along the greater curvature of the stomach (including 
subpyloric nodes) in transverse and right flexure cancers, as some of these patients have metastases in 
these nodes85.  
Increasing the number of examined lymph nodes in colon cancer specimens makes staging more 
accurate. This is important, as advanced stages (IIIa-c) regularly receive adjuvant chemotherapy, 
which improves prognosis significantly. Examination of more than 12 lymph nodes is associated with 
improved long time survival88, 89 indicating the advantages of the more radical D3 dissection.    
 
 
A      B 
     
Figure 6: Lymphovascular dissection in sigmoid cancer: D3 dissection 
No touch technique 
The term ‘no-touch technique’ was introduced by R. Turnbull in 196790 and implies central ligation of 
the vessels before mobilising the bowel, which should be manipulated as little as possible to avoid the 
intra-abdominal spread of cells from the tumour surface. Strangulation of the bowel lumen within the 
area of resection is advocated to reduce the risk of intra-luminal spread of tumour cells and 
implantation in the anastomosis. The benefit of this technique described by Turnbull91, Slanetz87 and 
Wiggers92 has been disputed93. Despite the lack of evidence, this technique is based on reasonable 
oncological principles and should be considered when operating colon cancer for cure. 
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II. Colon cancer with distant metastases 
If the distant metastases can be radically resected, there is a curative potential and the same 
oncological principles as listed above apply. Up-front chemotherapy is then to be considered. Whether 
first to resect the primary tumour, the metastasis or both simultaneously is an unsettled issue. In most 
cases, a tailored multimodal treatment should be given. Therefore, these patients should be evaluated 
by a multidisciplinary team. 
Most patients with distant metastases cannot be cured. Treatment is then palliative, and how to address 
the primary tumour is debatable93. If the tumour does not cause symptoms, the indication for resection 
is unclear94, 95. When symptoms are present, the treatment should be directed against these: by 
obstruction, an intraluminal stent may be considered in fragile patients when the tumour is located in 
the left colon; otherwise, operation with a bypass, diverting stoma or resection is required. Sometimes, 
bleeding may warrant a resection if the patient tolerates surgery.    
 
III. Colon cancer with emergency presentation 
Approximately 10-30% 96 of colon cancer patients present with acute symptoms, mostly because of 
obstruction (80-85%) or perforation (10-20%). Profuse bleeding rarely occurs. 
Treatment for acute colon obstruction (according to the Norwegian guidelines) depends on location: 
By right sided obstruction, a right hemicolectomy is recommended, or a bypass/diverting stoma if the 
tumour cannot be removed. By left sided obstruction, an intraluminal stent could be inserted for relief 
of symptoms97, either as a permanent palliative procedure or as a temporary ‘bridge to surgery’ 
followed by potential curative resection after one to two weeks98-100. Reports on stenting of colonic 
obstruction have been presented since the nineties, but this method was not used in our department 
before 2003.   
Stent placement is recommended by several authors in order to reduce postoperative morbidity and 
mortality and to avoid stoma formation following emergency operations97, 98, 100-102. The overall 
technical and clinical success rates of colonic stenting are reported to be 89-96% and 85-92%, 
respectively103, 104. Procedure related mortality is less than 1%, and the most common complications 
are recurrent obstruction (7.3-12%), migration of the stent (4.4-11.8%) and perforation (2.5-4.5%)103. 
Stenting is recommended both as bridge to surgery102, 104-109, and as permanent palliative treatment97, 99, 
102, 104-106, 110. Fit patients can then start chemotherapy immediately and avoid the immunosuppression 
and delay caused by surgery. If bowel function after stent placement is poor, bowel resection can be 
done at a later stage. In frail patients palliative stenting is a permanent treatment. 
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In case of stent failure, there are different surgical options, depending on situation; with curative 
intent, the operation can be done as one-, two- or three stage operations. In two-stage procedure 
resection with end colostomy (Hartmann’s operation) is performed initially, followed by reversing the 
stoma and restoration of bowel continuity after 3-6 months. A three- stage procedure includes 
proximal decompressing colostomy, colon resection after 1-3 weeks, and finally closure of the stoma 
after some months. In the non-curable situation and in frail patients, a diverting stoma or bypass of the 
tumour without resection is an option, even though associated with high mortality (>20%).     
In case of perforation, peritonitis or obstruction with a blind loop, primarily operation is mandatory.  
 
IV. Adjuvant treatment (AT) 
Following potential curative resection, the possibility of microscopic residual tumour tissue/cells in 
the patient exists. This is the target of postoperative adjuvant chemotherapy. Treatment over 6 to 12 
months with 5-fluorouracil (5-FU) combined with Leucovorin (FLV regimen) has improved five year 
DFS in stage II patients with 2-4%, and stage III with 10-15%111-114. The combination FLV with 
Oxaliplatin (FLOX regimen) has increased DFS in stage III patients115, 116. 
Combination of FLV and Irinotecan (FLIRI regimen) has not proved to add survival benefit in stage 
III patients117, 118, but could be effective in tumours with MSI119.  
The treatment with antibodies to Vascular Endothelia Growth Factor (VEGF) or Epithelial Growth 
Factor Receptor (EGFR) has to date not proven to be effective in adjuvant settings. 
AT to stage III patients < 75 years is widely used. The Norwegian guidelines have changed during the 
research project. Since 1997 FLV were recommended to stage III patients under 75 years. From 2003 
FLOX was recommended to fit patients up to 70 years of age, and since 2005 FLV was recommend to 
healthy patients up to 80 years.  
In stage II patients, subgroups with high risk of recurrence are considered for treatment120, and the 
Norwegian guidelines recommended chemotherapy to patients who have bowel perforation in the 
tumour area before or during the operation, and to those who have 8 or less lymph nodes examined. 
 
V. Treatment of colon cancer with peritoneal carcinomatosis 
Over the last 15 to 20 years, different treatment options in patients with PC of colorectal origin have 
been described. Selection of patients to operative treatment with extended 
cytoreduction/peritonectomy (removal of all visible tumour tissue from the peritoneum) combined 
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with hyperthermic intraoperative chemotherapy (HIPEC) has improved survival in selected patients. 
The extension of the intra-abdominal spread and the general condition of the patients are basis for 
selection. This treatment is resource demanding, and in Norway it is performed only in Oslo 
University Hospital, Radiumhospitalet. 
 
Histopathological examination 
The methods used by the pathologists to identify, retrieve and examine lymph nodes from the 
specimen vary. Mostly, formalin fixed specimens are examined after 3-5 days, however, with a risk of 
missing nodes in the mesocolic fat. Identification of nodes is easier when fat clearance techniques are 
utilised121-123, and increases the number of nodes examined.  
One slice is then obtained from each node, followed by Haematoxylin Eosin (HE) staining of 3-4 μm 
thick paraffin-embedded sections which undergo microscopic examination. Ultra-sectioning - 
obtaining multiple slices from each node - are not routinely used, nor is the use of 
immunohistochemical (IHC) examination or reverse transcriptase - polymerase chain reaction (RT-
PCR) to identify small ordinary metastases, micro-metastases (MM) or isolated tumour cells (ITC). 
Such techniques contribute to increase the detection rate of metastases.  
The sentinel node (SN) concept  
The concept was primarily described in the treatment of penis cancer, and is used regularly in 
treatment of breast cancer and malignant melanoma It is based on the hypothesis that if lymph node 
metastases are present in any node, metastases will also be present in the LN next to the primary 
tumour, defined as ‘sentinel nodes’. Extended examination of these nodes is then sufficient for 
accurate LN staging, including the identification of MM or ITC. Time and resource demanding 
examinations (Ultra sectioning, IHC, RT-PCR) is therefore necessary in only a limited number of LN.  
In colon cancer this concept has been evaluated in numerous studies, but with conflicting results124. 
We participated in a prospective study on SN121 which did not show any benefit of this method in the 
staging of CC.  
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Predictive factors 
Factors which have impact on the patients’ response to a certain therapy are called predictive factors. 
Some bio-molecular factors that predict the response to cytotoxic therapy have been identified, and are 
therefore important when allocating patients to different therapeutic regimens.   
The predictive value of K-ras mutation status in therapy with antibodies to epidermal growth factor 
receptors (EGFR) is well documented125-127, and in regular clinical use. 
Human cancer cells lines with disruption of TP53 have shown reduced therapeutic response to 
fluorouracil in experimental studies128, and reduced effect of FU-based chemotherapy has been 
reported in TP53mutated tumours has been reported129, 130.  However, the potential predictive value of 
TP53 mutation must be investigated in future studies. The research in this field is expanding rapidly, 
and opens up the perspectives of personalized medicine.  
 
Prognostic factors 
The prognosis of CRC differs widely among patients, and depends on a number of factors. Currently, 
the gold standard of prognostication is the clinicopathological staging based on the TNM classification 
system. Stage of the disease at presentation has profound effect on the prognosis. However, prognosis 
also differs between patients within the same TNM stage, and many clinical, histopathological and 
biomolecular markers have potential impact on outcome.  
Previously the research was focused on different clinical and histopathological factors and a limited 
number of protein markers, such as CEA. During the last two decades, an extended number of 
proteins, biomolecular and genetic markers have been subjects of intensive research, and both 
prognostic and predictive impact has been investigated. Such studies are, however, often small 
(underpowered), performed on selected materials and retrospective. Multivariate analyses with 
adjustment for known prognostic factors are necessary when investigating the effect of new factors, 
and very large, prospective studies are then needed. So far, despite many published recommendations 
to include new prognostic markers, no consensus has been reached to incorporate any of these in the 
daily routines.     
At the beginning of this study period (2003), the clinical prognostication of patients was mainly based 
on the TNM stage, and less attention was paid to other factors. Knowledge about prognosis is 
important for two main reasons; firstly, to identify patients in stage I-II at high risk of recurrence who 
might benefit of AT, and to identify patients in stage III with low risk of recurrence, who should not 
be over-treated with AT. Secondly, to decide structure and intensity of follow up programs; this 
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should be based on calculated risk of recurrence in the individual patient to avoid unnecessary and 
costly examinations.  
When our studies started, many factors had demonstrated prognostic impact in several studies and 
were therefore well established. Other factors with a possible prognostic impact had been identified, 
but the findings were equivocal, and new studies warranted. In the following factors with a definitive 
prognostic impact as per 2003, and those with equivocal impact, are presented separately.   
 
Histopathological prognostic factors  
Established histopathological factors at start of the studies 
The depth of tumour growth (pT), the lymph node status (pN) and the presence of distant metastases 
are independent prognostic factors. There is also a strong correlation between these three factors.   
Tumour (pT) stage: Advanced T-stage is associated with reduced long term outcome131. Patients with 
stage II tumours (pT3-4, pN0, pM0) experience recurrence in about 20-30% of the cases132, 133.  
Lymph node (LN) metastases: The presence of lymph node metastases is associated with reduced 
survival, and prognosis worsens with an increasing number of metastatic nodes134. For a correct 
interpretation of LN status it is necessary to know the total number of LN examined, which depends 
on the extent of the surgical dissection and the quality of the pathological examination, and to know if 
metastases are present and the number of metastatic nodes.  
Distant metastases: Tumours presenting with distant metastases have the poorest prognosis, which is 
obvious and well documented. We excluded these patients in most studies on prognostic factors. 
Histologic subtype is always reported if assessable. The prognosis is most favourable in 
adenocarcinomas and worst in small cell carcinomas135, 136. In adenocarcinomas, tumours with 
extracellular mucin in more than 50% of the tumour volume are classified as mucinous. These are 
most prevalent in men and in the right colon, and patients with mucinous tumours have reduced 
survival137.  
Tumour differentiation grade: The traditional assessments include high, middle, low and 
undifferentiated tumours. Lower differentiation grade is associated with poorer outcome131. Because of 
bias caused by inter-observer differences in assessments, a two grade system (high or low grade) has 
been proposed131, 138, but this is not implemented in clinical practise in Norway.  
Venous invasion: A negative prognostic impact of venous invasion is well documented, and it is 
recommended to include it in the pathological report131. Venous invasion is proposed as part of an 
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extended system for prognostication139, 140, but is still not included in the generally used staging 
systems. 
Lymphovascular invasion has been regarded as a step in the pathway of spread to the regional lymph 
nodes, and increases the risk of metastases in these nodes141, and is associated with poorer outcome131. 
Perineural invasion of tumour is reported to have a negative prognostic impact in most series142-144 
and is recommended to be routinely included in pathologic reports131, 136 . 
Tumour residual classification (R-classification) system defines the extent of residual tumour tissue 
in the patients following resection, and is based on histopathology, intraoperative exploration and 
preoperative radiological examinations. R-stage is strongly associated with outcome64, 145. R0 refers to 
the situation with neither macroscopic nor microscopic residual tumour tissue. R1 refers to 
microscopic tumour tissue at the resection margins, but without macroscopic tumour left in the patient. 
R2 refers to macroscopic residual tumour after surgery, locally or distant, found at laparotomy or by 
radiological examinations. A curative resection is usually defined as R0 resection, but in some studies 
R1 resected patients are also included, (not all patients develop recurrence after a R1 resection).  
Histopathology; not well established prognostic factors 
Number of examined lymph nodes: The problem of potential under-staging has led to research on 
the prognostic impact on number of examined lymph nodes, showing an association between low 
number of examined lymph nodes and poor outcome in terms of recurrence and survival in stage (I-)II 
patients88, 146-148, whereas results in stage III are diverging88, 147, 149. At the start of these works,  
examination  of at least 12-14 lymph nodes was recommended65, but the minimum number of nodes 
needed for correct staging and prognostication varied among studies150-154.  
Lymph node ratio (LNR): LNR is the ratio of positive LN to the total number of examined LN in a 
specimen. At the beginning of our studies, the prognostic impact of LNR was not investigated in colon 
cancer patients. Most studies are published after 2005155-160, and demonstrate a significant prognostic 
impact in stage III patients.  
Lymph node size:  It is unclear if LN size is of prognostic significance: Up to 77% of metastatic 
nodes are less than five mm in greatest diameter161-164. LN volume was not of prognostic significance 
in the study by Wong et al.165. However, these reports are contradicted by two studies, one showing 
significantly higher proportion of metastases in lymph nodes > 10 mm166 and another  showing size > 
10 mm as an independent prognostic factor in stage III patients167.  
Micrometastases (MM) / isolated tumour cells (ITC) in lymph nodes (LN): Metastases of 
colorectal origin are defined according to size; Ordinary metastases as deposits of tumour cells > 2 
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mm in diameter, MM as deposits between 0.2 and 2 mm of size, and ITC as malignant cell clusters 
less than 0.2 mm or single isolated tumour cells63, 65. Ordinary metastases are normally detected in 
routine microscopic examination of HE stained samples. This method is cheap, easy and little resource 
demanding compared to more advanced methods, like IHC and RT-PCR, which are required to detect 
MM and ITC. The presence of MM/ITC has been reported in up to 30% of stage I/II patients when 
using IHC technique to examine the LN168-173.  
Despite the logical assumption that spread of viable tumour cells (as ITC or MM) to the 
lymphovascular draining system might lead to recurrence and thus have impact on survival after 
potential curative surgery, the results varies among reported series168, 171, 174-177. In 2007, Compton 
stated that the prognostic significance of minute tumour deposits in regional lymph nodes remains 
unclear178. This important clinical issue was investigated in Paper 3, which is a follow up of the 
patients included in our two-centre study of the SN concept in the surgical treatment of CC  published 
in 2008121.  
Host lymphoid response to tumour (Crohn’s like lymphoid reaction) is as an expression of a more 
powerful immune response in the host, and has been reported to predict a better survival179-181, findings 
contradicted by other authors182-184. It has therefore been evaluated with evidence grad IIB as not 
sufficient studied for routine documentation like lymphovascular and venous invasion136. 
 
Clinical prognostic factors 
Established clinical factors at start of the studies 
Emergency presentation (obstruction, perforation): The incidence and causes of emergency 
presentation of CC is described above (page 22). 
Postoperative mortality (10-25%)185, 186 and morbidity (>50%) are increased in patients who have 
undergone emergency operation187-191.  
Since the  early eighties, patients operated for obstruction have been reported with poor long term 
survival144, 189, 191, findings confirmed in later studies143. In a German multi-centre study from 1994192, 
overall survival was 33% and 51%, respectively in emergency versus elective patients. The 
corresponding figures for relative survival were 47% and 65%, respectively. Patients admitted 
emergently have more advanced tumours and consequently the rate of curative resection is lower185, 
193. However, even after curative resection five year survival is lower than following elective 
operation187, 188, 193, 194. In 2006, McArdle et al. reported poor outcome in emergency patients presenting 
with the symptoms blood loss, obstruction or perforation 195   
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Adherence to other organs: The tumour might adhere to neighbour organs / structures due to direct 
invasion of tumour tissue (pT4), or due to inflammatory adherence. It is not possible to distinguish 
between these causes intra-operatively. Therefore, ‘en-bloc’ resection of the tumour-bearing bowel 
segment and a part of (or the whole) affected organ should be carried out196. If radical resection with 
microscopic free resectional margins is achieved in a pT4 tumour, the outcome is comparable to that 
of a pT3 tumour138, and ‘en bloc’ resection is the gold standard in these situations76, 77. If en bloc 
resection is not performed, there is a risk of involved margins and there is also an increased risk of 
intraoperative tumour perforation, which is associated with increased risk of recurrence and reduced 
survival82.  
Clinical factors; prognostic impact uncertain 
Tumour site: A Norwegian study from 1987 demonstrated increased mortality for patients with 
tumour in the distal colon and rectum197. Aldridge et al.198 reported increased rates of obstruction and 
recurrence, and reduced age adjusted 5-year-survival in tumours located in the splenic flexure. In 
contrast, single centre studies reported no influence of tumour location on prognosis138, 199, 200. Gupta 
reported in 2005 slightly higher survival in left sided cancers201, but in the Norwegian national study 
from 2004202, there was reduced relative survival in rectal cancer patients, but no difference between 
right and left colon.  
Age:  The incidence of CRC increases with age, as well as the morbidity and mortality from other 
causes than cancer. Overall survival is therefore decreased in older patients with CRC. The impact of 
age on cancer specific survival or relative survival varies in reported studies. An independent impact 
of age has been reported by some144, 202, whereas others describe no impact on survival or local 
recurrence138, 199.  
Gender: The association between gender and outcome is unclear, as studies are reporting conflicting 
results. An assumption of difference seems logical, as the general patterns of diseases are different 
between the genders. This could also imply differences in tumour biology and in host related 
immunological response to the disease, as well as different response to adjuvant therapy. 
Blood loss / Perioperative blood transfusion (PBT): some patients presents with severe anemia, and 
some have perioperative blood loss, and need PBT.  The effect of PBT on oncological outcome in CC 
patients has been investigated for decades. Several retrospective reports from the 1980ies were 
inconclusive203-208. A review of 31 retrospective studies in 1991209 was inconclusive. Several later 
reports showed no prognostic impact of PBT210-213. In contrast, Edna and co-workers from Norway 
found that PBT had a negative impact on survival214, and increased the rate of postoperative 
infections215. The latter finding was supported in a later review including 20 articles published in 1986 
– 2000216. 
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Symptom duration: In 1981, McDermott et al. reported that patients with symptom duration less than 
3 months had lower CSS than the other patients217. Several other series during the eighties showed 
significantly shorter duration of symptoms in more advanced stages218, and better prognosis with long 
duration of symptoms138, 144, 219. In the last two decades, few studies have included this variable, most 
likely because of the difficulties in defining and registration symptom duration. This parameter is not 
included in our local database.    
Surgeon related factors: Surgery for CRC is demanding, and requires surgical skill and experience. 
The formal levels of skill can be graded in three groups; the trainee / resident, the general surgeon, and 
the specialized colorectal surgeon. In all three groups the volume of colon cancer operations may vary 
widely.  
Studies have shown a more favourable outcome in patients operated by specialised colorectal 
surgeons200, 220, but there are also differences among surgeons with the same level of formal 
specialisation221, 222. In a more recent report, there was no significant difference in 30-day mortality 
between the different surgeons223. However, most series report significantly higher postoperative 
morality when operated by low volume surgeons224-226.  
Hospital related factors: Several authors have reported improved outcome in large volume hospitals 
compared with low volume hospitals192, 227-229, and Blomqvist et al. found better survival in 
regional/University hospitals versus small local hospitals230. These results are contradicted by other 
reports showing no survival difference between high and low volume hospitals231, 232. Most studies224-
227, but not all231, 233, report better results in high volume hospitals. There are however no consensus on 
definition of low and high volume hospitals. 
Biomolecular factors 
There has been intensive research on the prognostic effect of a diversity of bio-molecular markers the 
last 15-20 years. Various terms for such markers are used in the literature; biomarkers, molecular 
markers, biomolecular markers and genetic markers. An immense development in laboratory methods, 
including large scale analyses of protein expression using tissue micro arrays, new methods for 
sequencing DNA and RNA, and many other methods, have made such studies feasible. Studies on the 
genome, transcriptome and protein level are performed, and tissue from the primary tumour and 
metastases, blood, faeces and urine can be analysed. A detailed description of all these factors is 
beyond the limits of this thesis.  
Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion and found in the blood of 
some 50% of CRC patients. It is an established prognostic factor and used in clinical practice, and will 
therefore be discussed. 
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CEA: Preoperative elevation of CEA, and the degree of elevation, is associated with increased risk of 
recurrence234 and decreased long term survival235, 236 with the highest level of evidence131. Also when 
analysing subsets of patients (stage I/II), preoperative CEA is reported to be a significant prognostic 
factor236.  
Following potentially curative resection, CEA may rise if recurrence occur, and the reported 
sensitivity and specificity are  64% and 91%, respectively237. Even when normal preoperative, it will 
rise in at least 50% of patients with recurrent disease238, making it useful in routine follow up 
programmes.    
 
Follow-up  
The main objectives of systematic follow-up after potential curative treatment for CRC are to detect 
recurrence as early as possible, thereby securing optimal treatment, whether curative or palliative. 
Moreover, surveillance should detect synchronous or metachronous disease; and finally, follow-up is 
required for registration of treatment outcome.  
Secondary objectives are management of late complications after surgery, follow-up of adjuvant 
chemotherapy, counselling regarding risk factors and information about signs of recurrent disease as 
approximately half of the recurrences occur between follow-up consultations. Inclusion in a 
surveillance programme should also convey a feeling of security. 
According to the Norwegian guidelines, patients in TNM stage II - III who are candidates for curative 
resection or chemotherapy in case of recurrence, should be included in a follow-up programme. 
General health and comorbidity have to be considered, particularly in elderly patients. Normally, 
patients older than 75 years of age are not included, but individual assessments are made in patients up 
to 80 years.  
Stage I patients are not included in structured follow-up programmes, as the risk of recurrent disease is 
very low. A second colonoscopy should be made after five to ten years for the detection of 
metachronous disease. The cumulative risk for developing a second primary tumour is approximately 
2% after five years, and 3-4% after ten years239, 240. 
The benefit of structured follow-up after potential curative operation for CRC has been debated241, 242. 
A meta-analysis from 2007 243 detected an overall survival benefit for patients included in structured 
follow-up programmes. However, specific recommendations were not given, mainly because of 
heterogeneity in the different studies included244-251. At present, three international randomised trials 
are recruiting patients: the GILDA trial252, the COLOFOL Study253 and the FACS Trial 2009 (web-
document available at http://www.facs.soton.ac.uk).                    
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Some 85% of recurrences occur during the first three years after surgery; follow-up should therefore 
be most intensive in this period. 
In the recently published Norwegian guidelines, follow-up, includes measurement of CEA, imaging of 
the liver, abdomen and chest, and examination of the colon / rectum according to the schedule 
presented in Table 3254. The first postoperative examination is made by the surgeon; otherwise, follow-
up could be made by the general practitioner.  
 The benefit of CEA is unsettled, sensitivity and specificity varying with different cut-off values237, 255. 
In cases with elevated CEA preoperatively, a control should be made four weeks after surgery. If CEA 
is not normalised, residual disease should be suspected.  
Contrast enhanced ultra sound (CEUS) is without carcinogenic side effects and has higher sensitivity 
(80-84%) and specificity (84-98%) than CT/MRI and is therefore recommended256, 257.  
Table 3: Recommended follow-up programme for patients operated with curative intent in whom 
resection of local recurrence or metastases could be indicated. 
 
Months after operation 
 
1¹  
 
6 
 
12 
 
18 
 
24 
 
30 
 
36 
 
48 
 
60 
 
CEA 
 
● 
 
● 
 
● 
 
● 
 
● 
 
● 
 
● 
 
● 
 
● 
 
CT scan of liver / abdomen 
 
 
 
●² 
       
● 
 
CEUS ²  
   
● 
 
● 
 
● 
 
● 
 
● 
 
● 
 
 
Low dose chest CT  
   
● 
 
 
 
● 
  
● 
 
● 
 
 
Colonoscopy or CT colonography 
         
● 
 
¹ At the first consultation, the surgeon should assess the clinical outcome and document 
histopathology. It should take place within four weeks for adjuvant treatment to be scheduled in due 
time if indicated.  
² CEUS six months postoperatively is base for subsequent examinations. By considerable steatosis or 
cirrhosis, CT scan should replace CEUS. In departments of radiology where CEUS is not offered, CT 
scans should be done. 
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Aims of the study/thesis 
Colorectal cancer surgery constitutes one of the principal fields of activity of our department. 
Continuous, prospective registration of all patients is mandatory for evaluation of treatment quality 
and outcome. Our project, in which we wanted to assess the quality of surgery and of the 
histopathological evaluation of resected specimens as well as the oncological outcome after surgery, is 
based on the Aker colorectal cancer registry. Close collaboration with the pathologists is important 
for postoperative staging and subsequent selection of patients for adjuvant chemotherapy. We 
suspected that histopathological factors of potential prognostic significance were inconsistently 
reported. Our principal aim was to investigate the prognostic impact of possible clinical and 
histopathological factors registered in our database. In addition, clinical characteristics, genetic 
mutations and long term outcome were investigated in the subgroup of patients presenting with PC at 
diagnosis. 
Our specific aims were: 
To evaluate survival in an unselected population based series of colon cancer patients (Paper 1) 
 
To identify clinical prognostic factors for long term outcome after surgical treatment of colon cancer 
(Paper 1) 
 
To evaluate short term outcome after surgery for colon cancer (Paper 2) 
 
To identify possible risk factors for postoperative mortality and complications in patients treated as 
emergency cases (Paper 2) 
 
To evaluate the prognostic impact on long term recurrence and survival of MM and ITC in regional 
lymph nodes from stage I/II colon cancer specimens (Paper 3) 
 
To examine clinical characteristics of colon cancer patients who presented with PC (Paper 4) 
 
To evaluate survival in patients with PC of colon cancer origin (Paper 4) 
 
To examine the TP53 mutation status in primary tumours from PC patients as compared with tumours 
in patients without PC (Paper 4) 
 
To evaluate longitudinally the quality of histopathological reports on colon cancer specimens (Paper 
5) 
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To investigate the prognostic impact of the number of examined regional lymph nodes following R0 
resection in stage I-III patients (Paper 5) 
 
To evaluate the prognostic impact of LNR in stage III patients (Paper 5)  
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Patients and methods 
Patients and database  
Our research project was initiated in January 1993. All patients with cancer of the colon and rectum 
admitted to our department were registered in a prospective database. Patients with colon cancer, i.e. 
with tumours located > 15 cm from the anal verge, were included in the present studies.  
During the period 1993 – 2005, our catchment area included approximately 210,000 inhabitants, 
increasing in 2006 to 270,000. Data supplied from the Norwegian Cancer Registry who receive copy 
of all pathology reports on colorectal cancer from all departments of pathology in Norway, secured the 
inclusion of all patients diagnosed with colon cancer during the study period.  
Preoperative diagnostic data, intra-operative findings and complications, histopathological data and 
postoperative morbidity were recorded.  
During the study period, patients younger than 75 years of age were included in a standardised follow-
up programme; patients > 75 years were included at the discretion of the surgeon. Data on recurrence, 
treatment for recurrence and death, including cause of death if known, were registered. The follow-up 
programme was in accordance with national guidelines and consisted of CEA control every third 
months for two years, then at three and five years postoperatively. Clinical examinations 
supplemented  with X-ray of the chest an ultrasound (US) of the liver was undertaken every 
six months for two years, then at three and five years. X-ray and US were replaced by CT 
scan in 2007. Colonoscopy was part of the diagnostic work-up; if missing or incomplete, it 
was performed postoperatively and repeated at one and five years.  
 
Study design / data quality 
The studies on survival and time to recurrence were observational cohort studies which included all 
patients admitted from 1993. The end of inclusion varies from 2000 (Paper 1) to 2009 (Paper 5), 
ensuring the necessary observation periods for survival analyses of minimum twelve months (Paper 5) 
(Figure 7). All patients from the catchment area were consecutively registered and we therefore 
consider the studies to be prospective and population based. 
Paper 3 comprises patients from two centres: Akershus University Hospital (AUH) and Oslo 
University Hospital, Aker (OUHA). The study was conducted from AUH, which included 140 patients 
from December 2000 to September 2005. OUHA included 53 patients (Figure 1).  
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Comparison of TP53 tumour suppressor gene mutations in PC and non-PC patients presented in paper 
four was designed as a matched case-control study. A historic cohort with known mutation status from 
the same (Aker) population was chosen for comparison instead of patients without PC as a full 
mutation analysis of the Aker patients without PC would have been resource demanding and time 
consuming and not possible to perform within the time limits of the studies. The historic cohort was 
taken from the same region and matched the Aker non PC patients with regard to gender, tumour 
location and stage, but a selection bias cannot be ruled out. 
The quality of preoperative examination, intra- and postoperative data was high, and patients were 
registered at discharge from the hospital. Some patients were not registered prospectively because they 
were transferred to another department (internal medicine) or died in hospital leading to autopsy not 
reported to the study secretary. These patients were registered retrospectively when identified by the 
hospital registry and the Norwegian Cancer Registry. In Paper 2, additional data on emergency 
patients were registered retrospectively. 
Follow-up data were registered on patients included in the follow-up programme; however, for 
patients who moved from the catchment area during the study period, some data were missed. All 
patients were followed at the department. Time and causes of death were collected from hospital 
records for those who died in hospital. For others, data were obtained from the Norwegian Cause of 
Death Registry, which has a delay in registration extending to three years. In addition, the causes of 
death reported on the public death certificate may in some cases be erroneous due to low autopsy rates.         
 
Survival analyses 
In the first paper, we performed overall (OS) and relative survival (RS) analyses on prognostic factors 
mainly to avoid possible false causes of death as autopsy rates were low during the study period. OS 
does not distinguish between causes of death; RS is adjusted for the general mortality in the population 
of interest with regard to gender, age and time period. We therefore consider these analyses to be more 
reliable than cancer specific survival (CSS) in which the exact cause of death has to be known in all 
cases. In Paper 4 however, the causes of death were known in all stage IV patients. We therefore used 
CSS analyses with definitions of event, censors and ignored cases as described by Punt et al.258 (Table 
5).  
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Year       
1993     Start of registration colon cancer patients at the Department of Gastrointestinal Surgery  
 
 
2000    --- 
 
2002    ---   -  -  -  -  -  -  -  -  -  -  -  Start inclusion Paper 3     
2003    ---    - - - - - Analyses Paper 1 
2004    --- 
2005    --- 
 
2006    --- 
 
 
2007    --- 
 
2009 ---    -  -  -  -  -  -  -  -  -  -Analyses Paper 3 - - Analyses Paper 4    
         
 
2010    ---     -  -  -   -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -   Analyses Paper 5 
 
Figure 7: Inclusion periods of the different studies / papers: 
Paper 1: Tumour location is a prognostic factor for survival in colonic cancer patients      
Paper 2: Short term outcome after emergency and elective surgery for colon cancer                        
Paper 3: Lymph node micrometastases and isolated tumor cells influence survival in stage I and II 
colon cancer                                    
Paper 4: Peritoneal carcinomatosis of colon cancer origin: Highest incidence in women and in patients 
with right sided tumours                                   
Paper 5: Prognostic impact of lymph node harvest and lymph node ratio in colon cancer patients 
End of inclusion 
Paper 1 (N=627) 
End of inclusion 
Paper 3 (N=53) 
End of inclusion and 
analyses Paper 2 
(N=1129) 
End of inclusion Paper 5 
(N=1481) 
End of inclusion 
Paper 4     
(N=1124) 
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Disease free survival (DFS) would have been another option; however, the standard follow-up 
programme only includes patients younger than 75 years of age, and recurrences in elderly patients 
were missed. In Paper 3, we applied DFS analyses as all patients were included in the follow-up 
programme and the recurrence status was known in all patients.  
OS and time to recurrence (TTR) were used in Paper 5, adopting the definitions of endpoints listed in 
Table 5258. We accepted the application of TTR analyses as we considered the quality of data on 
causes of death to be sufficiently high after corroboration with the Norwegian Cause of Death 
Registry. However, the possibility of false cause of death in some cases cannot be ruled out.  
 
Histopathological examinations 
All specimens were examined at the Department of Pathology, Oslo University Hospital Aker. Eight 
consultant pathologists were involved during the study period. After formalin fixation, paraffin 
embedded blocks was prepared, followed by standard microscopic examination of 3-4 μm 
haematoxylin-eosin (HE) stained sections. Tissue-sections from primary tumour(s), resection margins 
of both bowel ends, of circumferential mesocolic resection margins and all identified lymph nodes 
were examined.   
In Paper 3, all identified lymph nodes in stage I and II patients were examined immunohistochemically 
using a monoclonal antibody to cytokeratin CAM 5.2 (Becton-Dickenson, mountain View, CA, USA) 
as described in the paper. All immunostained sections were examined by two pathologists at each of 
the two participating hospitals.  
TNM stage classification 
The prospective registration of patients began on 1 January 1993 and inclusion periods varied as 
shown in Figure 1. Until 2003, when results from our first study were analysed, we applied the TNM 
classification system according to the UICC/AJCC fourth edition. In the subsequent studies, the sixth 
edition was applied with conversion of data for patients registered earlier than 2003.  
 
DNA isolation and TP53 mutation analyses (Paper 4) 
DNA isolation was carried out on formalin-fixed, paraffin-embedded tissue samples from 55 PC 
patients. For each tissue sample the tumour area and differentiation grade in a 5μm HE-stained section 
were evaluated by a pathologist. If necessary, tumour tissue was manually dissected prior to sectioning 
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for DNA isolation. DNA was extracted by standard procedure from four consecutive 25μm sections of 
each sample. Tumour DNA from two additional patients was isolated by standard phenol – 
chloroform extraction from fresh frozen tissue.  
Each of the exons 5, 6, 7 and 8 was amplified in independent polymerase chain reactions (PCR) using 
flanking intronic primers, which generated products of 289, 267, 218 and 281 bp, respectively (Table 
4). Each PCR was performed according to the procedure shown in Table 4a.  The direct sequencing 
reaction was performed using several different inputs of PCR product. The same primers were used as 
for the initial PCR. The resulting sequence product was further purified using Millipore multiscreen 
plates and subjected to further sequencing by a 3730 DNA Analyzer (Applied Biosystems). 
Owing to the possibility of false positives resulting from formalin fixation32, 53, 259, 260, all DNA 
sequences of interest for each sample were submitted to two independent PCR and sequencing 
analyses.  
Tumours with mutations and those in which the mutations could not be scored were submitted to a 
second new PCR procedure (Table 4b). The high-fidelity polymerase lowers the probability of errors 
introduced by the polymerase itself. The results were also compared with IARC TP53 mutation 
database1, version R12, November 2007. 
 
 
 
Table 4: Polymerase chain reactions performed with a) HotStar polymerase and b) HotStar HiFi 
polymerase  (QIAGEN, GmbH, Hilden, Germany) for TP53 mutation detection. 
 
a)  HotStar polymerase          
  
HotStar Buffer  
without MgCl2 
MgCl2 
(mM) 
dNTP 
(mM) 
Polym
erase 
(U) 
Q -
solution 
5' primer 
(pmol/μl) 
3' primer 
(pmol/μl) 
DNA 
(ng) 
Anneal  
temp (°C) cycles 
Product  
size (bp) 
5' Primer 
sequence 
3' Primer 
sequence 
ex5 1x 1.5 0.17 1.0U 0 0.2 0.2 50 54 40-45 289 
TTC AAC TCT 
GTC TCC TTC 
CT 
GCA ATC AGT 
GAG GAA TCA 
GA 
ex6 1x 2.5 0.17 1.0U 0 0.2 0.2 50 54 40-45 267 
GCT GCT CAG 
ATA GCG AT 
CCA CTG ACA 
ACC ACC CTT 
ex7 1x 1.5 0.17 1.0U 0 0.2 0.2 50 54 40-45 218 
AGG CGC ACT 
GGC CTC ATC 
TT 
AGG GGT CAG 
CGG CAA GCA 
GA 
ex8 1x 2.5 0.17 1.0U 0 0.2 0.2 50 58 40-45 281 
TTG GGA GTA 
GAT GGA GCC 
T 
AGG CAT AAC 
TGC ACC CTT 
GG 
                                                          
1 www-p53.iarc.fr/index.html 
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b)  HotStar HiFi polymerase          
  
HiFi Buffer  
with dNTP 
MgSO4 
(mM) 
dNTP 
(mM) 
Polym
erase 
(U) 
Q-
solution 
5' primer 
(pmol/μl) 
3' primer 
(pmol/μl) 
DNA 
(ng) 
anneal  
temp (°C) cycles 
Product  
size (bp) 
5' Primer 
sequence 
3' Primer 
sequence 
ex5 1x 2.5 1.0 1.25 1x 1.0 1.0 50 56 40 289 
TTC AAC TCT 
GTC TCC TTC 
CT 
GCA ATC AGT 
GAG GAA TCA 
GA 
ex7 1x 2.5 1.0 1.25 1x 1.0 1.0 50 56 40 267 
GCT GCT CAG 
ATA GCG AT 
CCA CTG ACA 
ACC ACC CTT 
Ex8 1x 2.5 1.0 1.25 1x 1.0 1.0 50 56 40 281 
TTG GGA GTA 
GAT GGA GCC 
T 
AGG CAT AAC 
TGC ACC CTT 
GG 
 
 
Statistical methods 
For comparison of proportions, Pearson chi squared or Fisher Exact test were used, as appropriate. 
When comparing means in two independent samples, student t-test was used if data were of normal 
distribution. If data were skewed, a non-parametric test was used; means in two independent samples 
were compared by Mann-Whitney U test and in analyses of three or more independent samples, 
Kruskal-Wallis H test was used. For multivariate analysis on prognostic factors for mortality and 
complications (Paper 1) and risk factors for PC (Paper 4), binary logistic regression was used, as step-
forward model including all factors with significant differences (P < 0.05) in univariate analysis. 
Overall survival, disease free survival, cancer specific survival and time to recurrence were calculated 
with Kaplan Meier Method, and Log-rank test was used for comparison of curves. The endpoints were 
defined according to Punt et al.258 (Table 6) as described above. For multivariate evaluation of 
independent prognostic factors, cox regression analyses were performed, as step-forward model 
including all factors with significant impact in univariate analysis.   
Relative survival was calculated with adjustment for general mortality in the population according to 
gender, age and time period, using Statistics Norway (www.ssb.no) as source of required data.  
In all tests, a P value of < 0.05 was considered statistically significant. 
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Summary of papers 
Paper 1:  
Tumour location is a prognostic factor for survival in colonic cancer patients. 
Prognostic factors for survival were evaluated in a consecutive, unselected series of 627 colon cancer 
patients admitted to Department of Gastrointestinal Surgery, Aker University Hospital, between 1993 
and 2000. Median follow-up was 44 months.  
A total of 501 (81%) patients were operated on with major tumour resection. The rate of major 
resection was lowest for tumours located in the splenic flexure (73%) and the descending colon (67%). 
The intention was curative in 410 (65%) patients, of whom 378 (60%) had a R0 resection and 32 (5%) 
a R1 resection.  
Five year OS was calculated with the Kaplan-Meier method. Five year RS was estimated with 
adjustment for age, gender and time period related mortality of the general population in the area.  
For all patients admitted, five year OS rate was 41%. Five year RS was 50% in females and 52% in 
males. Following resection with curative intent, the five year OS was 59% with no difference between 
genders; five year RS was 74% in females and 79% in males.  
Following R0 resection, five year OS was 62% and five year RS was 78% in females and 82 % males, 
a difference which was not statistically significant. 
Cox regression analyses were performed to identify independent prognostic factors. Patients with 
tumours located in the transverse colon, splenic flexure and descending colon (these locations were 
stratified into one group) had reduced survival (hazard ratio [HR] 1.8, P=0.048) compared to patients 
with tumours located in the right colon. 
Blood transfusion of more than 2 units during hospital stay (HR 1.8, P=0.008), emergency operation 
(HR 1.7, P=0.005), advanced TNM stage (Stage II: HR 1.8, stage III: HR 2.9) and advanced age 
(P<0.001) were independent prognostic factors for reduced survival. 
Patients with tumours in the splenic flexure and descending colon have reduced survival due to a low 
resection rate. However, additional factors also contribute; even following major resection, tumour 
location in the transverse colon, splenic flexure and descending colon were independent negative 
prognostic factors in multivariate analyses. 
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Paper 2: 
Short term outcome after emergency and elective surgery for colon cancer 
Postoperative mortality and complications were evaluated in a consecutive, population based series of 
1129 patients registered in the period 1993 – 2007, and results following elective and emergency 
surgery were compared.  
A total of 850 (75%) elective and 279 (25%) emergency patients were admitted; 999 (89%) underwent 
surgical treatment and 924 (82%) had major resections. The rate of major resection was 58 % in 
emergency patients and 90% in elective patients (P<0.001). After resection 82% of emergency 
patients and 98% of elective patients had a primary anastomosis (P<0.001).  
The main causes of emergency admittance were obstruction (80%), obstruction with proximal 
perforation 5% and perforation in the tumour area (8%). 
After major resection, the mortality rate was 3.5% in elective and 10 % in emergency patients 
(P<0.01), and the overall complication rates were 24% and 38%, respectively (P<0.01). The odds ratio 
for mortality was 2.5 (1.4-4.5) and for complications 2.0 (1.4-2.8)   
In patients operated on for left sided obstruction (without perforation), the mortality rate following 
Hartmann’s procedure was 19%, whereas it was 3% following resection with primary anastomosis 
(P<0.01). 
High mortality rates were noted in patients who underwent surgery without resection, 17% in the 
elective and 24% in the emergency setting (P=0.45). Overall complication rates were 25% and 45 %, 
respectively (P=0.07) 
For all patients who underwent surgery, logistic regression analyses demonstrated that emergency 
operation (P=0.001), male gender (P<0.01), advanced age and advanced TNM stage were associated 
with increased complication rates. Emergency operation (P<0.001), advanced age and ASA (American 
Society of Anaesthesiologists) score IV (P<0.001) were associated with an increased risk of 
postoperative death. 
In conclusion, the study shows that a large proportion of patients with colon cancer presents with acute 
symptoms. Emergency operation is associated with high mortality and complication rates. Hartmann’s 
procedure and surgery without resection was associated with a particularly high mortality rate, 
probably due to patient selection. Alternatives to emergency surgery should be considered but need 
further evaluation in future studies. 
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Paper 3: 
Lymph node micrometastases and isolated tumour cells influence survival in stage I and II colon 
cancer 
The influence of MM and ITC on recurrence rates and the survival – using time to recurrence (in the 
article incorrectly called disease free survival) as endpoint, was investigated in this prospective study 
of 193 patients with colon cancer operated on at two centres between 2000 and 2005. Median follow-
up was five years. 
All retrieved lymph nodes were examined by routine microscopy in haematoxylin and eosin-stained 
sections. If no metastases were identified in any node, all nodes were examined 
immunohistochemically with the monoclonal antibody CAM 5.2. 
Ordinary metastases were defined as malignant cell cluster larger than 2 mm in diameter; MM as 
malignant cell clusters with diameter between 0.2 and 2 mm; and ITC as malignant cell clusters less 
than 0.2 mm in diameter or single tumour cells.  
Ordinary metastases were found in 67 (35%) patients, leaving 126 patients in stage I/II. In these, 
immunohistochemistry detected 6 (5%) patients with MM and 33 (26%) with ITC.  
There were 31% recurrences in stage III and 12% in stage I/II patients (P=0.002). In stage I/II patients 
with MM/ITC, recurrences were seen in 23%, whereas 7% in the MM/ITC negative group had 
recurrent disease (P=0.01).  
Five year TTR was 91%, 86% and 66% in stage I, II and III, respectively (P=0.002). In stage I/II, TTR 
was 75% for patients with MM/ITC and 93% for patients without MM/ITC (P=0.012). When 
analysing stage I (n=39) and II (n=87) separately, there was a trend towards improved survival in 
patients without MM/ITC (P=0.06 in stage I and P=0.07 in stage II, respectively). There were no 
significant differences in recurrence rates or TTR between stage I/II and stage III patients with 
MM/ITC. 
Cox regression showed that the presence of ordinary lymph node metastases (HR 4.8, P=0.001) in 
stage I-III patients, as well as MM/ITC (HR 3.5, P=0.02) in stage I/II patients, were independently 
associated with lower TTR. 
In conclusion, the presence of MM/ITC in the mesocolic lymph nodes of stage I/II patients has a 
statistically significant negative prognostic impact. The prognosis in patients with ITC is probably 
similar to that of patients with MM and not much different from the prognosis in stage III patients. 
Larger studies are needed to confirm these findings.   
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Paper 4: 
Peritoneal carcinomatosis of colon cancer origin: Highest incidence in women and in patients 
with right sided tumours 
The incidence of PC was evaluated in a prospectively recorded series of all colon cancer patients 
admitted in the period 1993-2006. Clinical and pathological characteristics, survival and TP53 tumour 
suppressor gene mutation status in primary tumours were compared in patients with and without PC. 
A total of 1124 patients were included in the study. At the time of diagnosis, 94 (8.3%) patients had 
PC; 10% in women and 7% in men (P=0.05). PC was diagnosed at laparotomy (n=89) or by CT scan 
(n=5).   
PC patients were younger than patients without PC, median (range) age 71 (33-91) and 75 (30-96) 
years, respectively (P=0.002). The incidence of PC was 10.3% in right sided tumours and 6.2% in left 
sided tumours (P=0.025). Liver metastases were present in 33% of PC patients and in 17% of patients 
without PC (P< 0.001). Major resections were performed in 66 % of PC patients and in 84% of non-
PC patients (P< 0.001); emergency operations were more frequent in PC patients (34% vs. 18% in 
non-PC patients).  
PC patients were compared with patients with distant metastases at other sites (n=201): in PC patients, 
tumours were more often right sided (69% in PC patients vs. 51% in non-PC patients, P=0.006); in 
those who underwent major resection, PC patients had more advanced pT-stage (pT4 in 65% of PC 
patients vs. 17% in non-PC patients, P<0.001).  
In multivariate analyses of all patients following major resection (n=928), pT4 stage (OR 10.4, pT1-2 
used as reference, P=0.003) and stage pN+ (OR 3.2, P=0.002) were independently associated with PC.  
CSS was median 9 (range 0-60) months in PC patients. Patients with a single metastatic peritoneal 
deposit (n=13) had better survival, median 31 months (P=0.03). 
TP53 mutation status could be fully scored in 49 patients with PC. Mutation status being unknown in 
patients without PC, comparisons were made with a group of 148 non-PC colon cancer patients from a 
historical multicentre series treated in the period 1987-198941, 53, 261. Patients in the historical series 
were  younger than non-PC patients in the unselected series, median age 71 and 75 years, respectively 
(P=0.003), but were well matched with regard to gender, TNM stage and tumour location. 
Mutations in the TP53 gene were present in 57% of the PC patients and in 40% of non-PC patients 
(P= 0.04), odds ratio 2.4 (CI 1.2-4.8) in multivariate analyses. These analyses also confirmed that 
female gender was independently associated with PC (OR 2.5, CI 1.2-5.2) 
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In conclusion, this study demonstrates for the first time that PC of colon cancer origin is more frequent 
in women and in tumours of the right colon. PC patients were slightly younger than non-PC patients. 
PC was independently associated with mutation in the TP53 tumour suppressor gene, but selection 
bias cannot be ruled out when comparing mutation status with a historical series. 
 
Paper 5: 
Prognostic impact of lymph node harvest and lymph node ratio in colon cancer patients 
The prognostic impact of the total number of examined lymph nodes in stages I-III and of lymph node 
ratio in stage III patients were investigated. Development over time was evaluated by stratifying the 
patients into three groups according to dates of operation (1993-98 [first period], 1999-2004, 2005-
2009 [last period]). A total of 1481 patient were registered, of whom 950 stage I-III patients with R0 
resection were included in the analyses.  
Median number of lymph nodes increased from 7 during the first to 15 during the last period 
(P<0.001). The proportion of patient with >12 nodes increased from 18% to 85% (P<0.001). During 
the last two periods, 33% had stage III disease compared to 25% during the first period (P=0.02).  
LNR in stage III patients was median 0.33 during the first period decreasing to 0.14 during the last 
period (P<0.001). 
OS in all patients improved from 39% to 46% during the study period (P=0.002). TTR improved from 
81% to 95% (P=0.02) in stage I patients and from 66% to 85% (P=0.003) in stage II patients. 
Following R0 resection, increased number of examined lymph nodes was associated with improved 
OS and TTR in both univariate and multivariate analysis.  
Stage III patients were separated into four categories according to quartiles of LNR. The proportion of 
patients in the lowest quartile (0-0.10) increased from nine % during the first period to 33 % during 
the last period (P=0.002). 
High lymph node ratio was significantly associated with poor OS and TTR, 40% vs. 70% and 46% vs. 
83% in the groups with highest and lowest LNR, respectively. Multivariate analyses confirmed the 
prognostic impact of LNR. 
Selection bias is unlikely in this prospective, single centre population based series. Surgical technique 
has probably not changed much during the study period, but the quality of the pathological reports 
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improved. Therefore, improved pathological examination most likely explains the increase in the 
number of investigated lymph nodes, although other factors cannot be ruled out.  
In conclusion, OS in all registered patients improved during the study period, in accordance with 
national data. There are probably several reasons for this improvement. In patients who underwent 
curative resection, improved pathological examination with evaluation of more regional lymph nodes 
was associated with stage migration, which probably contributed to the improved stage specific 
survival. In stage III patients, LNR was a stronger prognostic factor than the total number of examined 
lymph nodes.      
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General discussion  
Curative treatment of colon cancer is based on surgical resection of the tumour bearing bowel segment 
with the regional mesocolic lymphovascular pedicle, containing the lymph nodes draining the tumour 
area. There are three main pathways of spread of the disease; haematogenous, lymphatic or direct 
spread of tumour cells to the abdominal cavity, all representing diagnostic and treatment challenges. 
The premise for cure is usually removal of all viable tumour tissue, although microscopic remaining 
tumour can be cured by adjuvant chemotherapy, and/or be destroyed by the immune-system of the 
diseased. Evaluation of outcomes is mandatory for quality assurance in a department, and research is 
necessary to further optimize the treatment, which must be individualised according to many factors 
with influence on patient tolerance for different treatment modalities, and impact on the long term 
results. Our research project with a local registry was founded to make this possible. 
 
The database 
These studies are based on a cohort containing all patients with colon cancer treated at a single 
institution from 1993 to 2009. Consecutive registration of patients required participation of all 
surgeons involved in the treatment and follow-up of patients. The registration was performed on case 
record forms (CRF), and the data were then entered into a database by researchers involved in the 
study project, or by a secretary trained in such registration. The CRF with clinical information on 
initial treatment was supposed to be finalized at discharge after the first hospital admission (or out-
patient visit in those not treated as in-patients).  
The follow-up of the patients was performed at the department during the entire study period, and all 
blood tests and radiological investigations were taken at the hospital. Follow-up data were also noted 
on special CRF’s by the surgeons.  
The compliance of the surgeons varied and some information was registered with some delay, either 
by the surgeon who had missed the primary registration, or by researchers more directly involved in 
the research project. To avoid missing cases, the database was checked against the patient 
administrative system in the hospital and against the Norwegian Cancer Registry. Such control 
procedures were not made, but in relation to publication of results. Updating the database at the end of 
the study period revealed that a maximum of 1% of patients were missing in previous publications, 
and it is unlikely that missing data had significant impact on the results and conclusions.  
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Study endpoints 
The studies were mainly focused on prognostic factors for survival in patients who underwent a 
(potentially) curative resection (Paper 1, 3 and 5). The primary endpoints were Relative survival (RS) 
and Overall survival (OS) in Paper 1 and 5, Cancer specific survival (CSS) in Paper 4, and Time to 
recurrence (TTR) and Disease free survival (DFS) in Paper 3 and 5. 
Table 5: Definitions of endpoints in survival analyses according to a consensus conference in 2007 
described by Punt et al.258.      
 
Event 
Disease Free 
Survival 
Time To 
Recurrence 
Cancer Specific 
Survival 
Overall 
Survival 
Locoregional recurrence E E I I 
Distant metastases E E I I 
Second primary, same cancer E I I I 
Second primary, other cancer E I I I 
Death from same cancer E E E E 
Death from other cancer E C C E 
Non-cancer related death E C C E 
Treatment-related death E C C E 
Loss to follow-up C C C C 
 
E = event, C = censor, I = ignore  
  
OS and RS analyses are based on death of any causes, which is the most robust endpoint. These data 
has been conceived from the Norwegian Population Registry on a regular basis, and are correct. 
Relative survival is a useful surrogate marker for cancer specific survival when data on cause of death 
is unknown or uncertain. It describes survival in the study cohort related to the expected survival in the 
whole population, adjusted for gender, age and time period. Large, population based studies have used 
this method96, 192, 202, 230, 262, making comparison of results meaningful.  
49 
 
OS is often used in outcome studies. All deaths, regardless of causes, are then events (Table 6), and 
accordingly, the results are influenced by variations in non-cancer mortality in the population. 
Obviously, elderly patients will be at higher risk of death than younger patients, regardless of other 
factors included in the analyses.  
DFS is used with different definition across studies. In Paper 3, DFS was defined with death of the 
same cancer and local / distant recurrence as event. Death of other causes was censored, as done by 
others171. The correct definition, as described in the consensus report published in 2007 by Punt and 
co-workers258 (Table 5), includes recurrence of CC and death of any cause as events. DFS with this 
definition will give lower survival curves than TTR.   
In the last study on prognostic impact of lymph nodes (Paper 5), we used OS and TTR as endpoints. 
TTR is based on death of the same cancer and recurrence as events, and loss to follow-up and death of 
other causes as censors. This corresponds to our definition of DFS in Paper 3, and TTR would have 
been the proper term to use in that paper. TTR requires knowledge of all recurrences and the cause of 
death in all patients in the study cohort. We believe these data to be of good quality, but false death 
causes or missed recurrences in some cases cannot be ruled out. 
CSS was used in Paper 4 because the patients of interest had disseminated cancer with spread to the 
abdominal cavity or liver/lung. Event is death of colon cancer, other causes of death is censored, and 
recurrent disease and metastases are ignored (Table 5). As cause of death is known in all these 
patients, it gives a meaningful comparison of survival between patients with PC and patients with 
metastases in other locations.   
All survival analyses were performed using the Kaplan Meier method, with cut off after five years, 
corresponding 5-year-OS, RS, CSS and TTR. Most recurrences occur within three years after curative 
surgery, and recurrence is rare after five years. Observation shorter than five years would imply the 
risk of missing recurrences and death of cancer. After five years most deaths are not related to colon 
cancer. OS and DFS will therefore be highly influenced by non-cancer related events. The risk of 
having a false death cause (cancer related) increases, and might confound analyses of CSS and TTR. 
We therefore think that five-year survival is best for evaluation of long term outcome of colon cancer. 
 Cox regression analyses as a step-forward model were used for identification of independent 
prognostic factors for survival. All significant factors with P-value of 0.05 or less in univariate 
analysis were included.  
Comparing results from different studies and centres is often difficult, and results from meta-analyses 
should be interpreted with care. There are more reasons for this;  
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1: The methods used in the survival analyses are not defined, or only referred to as ‘5-year survival’ or 
similar. If the method is specified, the definitions of endpoints, i.e. events and censors, are often not 
clearly stated. Thus, comparison and interpretation of survival curves are difficult, and the results not 
reliable.   
2: Selection criteria for inclusion in studies may vary between different centres. Analyses are often 
made on subgroups, for example patients referred to specialized centres192. Inclusion criteria may be 
curative resection (R0 resection)199, operation with curative intent186, 188, 193, 234, or is not clearly 
stated138, 194, 263. These studies often lack information about the complete population from which the 
selection has been made, with a probable risk of selection bias. This problem is illustrated by the great 
variation in resection rates from 99%199, 96%264 to 71%96, R0 resection rates of 85%199,  77%192 and 
55%264, and the distribution of colon and rectum tumours264.   
In larger regional or national series, selection bias should be minimal, and relative survival96, 202, 230, 262, 
observed survival265, or both192  is often used, as detailed information on recurrences and causes of 
death often lacks. 
3: The definition of the criteria used for selection is often not clearly described, like the definition of 
resection with curative intent and curative resection87, 263.  
4: In some studies colon and rectum cancer are mixed87. It is generally accepted, that colon and rectum 
cancers have different properties, have different natural histories, and are treated differently. They 
should therefore be investigated separately.  
In paper 2 mortality and postoperative complications were the endpoints. Data on per and 
postoperative deaths are complete, making the result on mortality reliable. Patients with major 
postoperative complications are probably nearly completely registered, as these cases are highly 
focused on in the clinical practice with registration of both complication(s) and treatment in the 
patients’ records. Minor complications are probably missing in some cases.     
 
Prognostic factors 
A number of characteristics and properties of the tumour, the patient and the therapeutic team 
including the surgeon, pathologist, oncologist and the department/hospital have effect on the outcome 
of colon cancer, as presented in the introduction. Only a fraction of known prognostic variables are 
used regularly in clinical practice.   
In the present project we have studied a number of clinical and histopathological factors, in addition to 
analyses of TP53 mutations in patients with PC, and the results will be discussed in the following.  
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Tumour stage (Dukes’ - UICC/AJCC):  The patients were classified according to Dukes’ / TNM 
stage using the TNM classification system described in the ‘Patients and methods’ section. Tumour 
stage had a strong impact on prognosis and also influenced postoperative complication and mortality 
rates. Consequently, adjustment for stage was always performed in multivariate analyses.  
Residual tumour (R-stage): R2-stage has major prognostic impact, as described previously and 
shown in our studies. R1-stage also has some impact on prognosis. Adjustment for R-stage (or 
inclusion of only R0 / R0+R1 patients, as appropriate) was therefore performed in survival analyses 
when evaluating other prognostic factors. 
 
Clinical prognostic factors 
Tumour location: At the beginning of our study period, a possible prognostic impact of tumour site 
was not stated. Reported results were conflicting; Single centre studies showed no influence of tumour 
location on survival138, 199-201, 212, 234, as did the large Norwegian study from 2003202. Others reported 
adverse impact on postoperative mortality and long term survival in left sided tumours197, 198.  
Right versus left colon 
Differences in clinical and biologic characteristics266, 267, incidence201 and different genetic 
expressions268, 269 of tumours in the right and left colon has been described, and the heterogeneity of 
colon cancers has become obvious39. These differences might have impact on the prognosis. MSI 
tumours with good prognosis is more prevalent on the right colon41, 270, whereas CIN tumours with less 
favourable prognosis is more prevalent on the left side271.  TP53 mutated tumours occur more often in 
the left colon and these patients have reduced survival in a large, multinational study56.  
However, conflicting results are reported when comparing right- and left-sided tumours. The 
definitions of right versus left colon are not consistent; some define right colon as including 2/3 of the 
transverse colon198, but most commonly the entire transverse colon is included in the right colon, while 
the splenic flexure, descending and sigmoid (with or without the rectosigmoid junction) is included in 
the left colon201, 272. This definition was used in our study. Indeed, the exact location and classification 
of tumours in - and close to - the left flexure may be difficult, which might influence the reported 
results. In the present study no difference in outcome was found, whereas other studies have shown 
better prognosis in right sided tumours excluding the hepatic flexure197, the whole transverse colon273 
or part of transverse colon198.    
Right sided tumours were reported by Gupta et al. to present at a more advanced stage201. In this 
smaller study, no significant impact of tumour location on survival was found. In a large population 
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based prospective cohort from USA with almost 78.000 patients operated for CC272, the postoperative 
mortality was higher in patients with right sided tumours than in those with left sided tumours (4.0% 
vs. 5.3%), median age was higher (73 and 69 years respectively), the proportion of poorly 
differentiated tumours was higher (25% vs. 14%) and median survival was lower; 78 vs. 89 months 
(P<0.001). In adjusted multivariate analysis, HR for death within five years was 1.042 (P=0.001) for 
right sided tumours.       
Prognosis according to segmental location 
We also analysed prognosis according to tumour location in each segment of the colon, but the 
numbers were too small to reach conclusive results. Interestingly, a trend towards less favourable 
prognosis was found for tumours in the transverse, left flexure, and descending colon, respectively. It 
was also our clinical impression that tumours in these sites – especially in the left flexure – are 
surgically more demanding than tumours in other sites. We therefore combined these three segments 
in new analyses, and found a significantly reduced survival when comparing tumour location in the 
transverse-left flexure-descending colon with the other colonic segments.     
There are several possible explanations for poorer outcome at these locations: 
- The surgical procedure may be more difficult, as already mentioned. The risk of missing the 
correct mesocolic plane during the dissection is greater than during operations for tumours in 
other locations 
-  Both the transverse and the left flexure cancer might have metastatic lymph nodes at the 
origin of the middle colic artery, and central lymphovascular dissection should be performed. 
Possibly, the surgery was not radical enough in some cases.  
- Tumours in the descending colon and splenic flexure had a lower rate of major resection 
(Table 1, Paper 1), leading to reduced rates of curative operations. 
-  In addition, tumours in the descending and sigmoid colon were more often operated as 
emergencies (Table 1, Paper 1), with increased postoperative mortality and morbidity, as 
shown in Paper 2.  
However, in multivariate analyses of patients operated with curative intent, tumour location remained 
as independent prognostic factor after adjustment for gender, age, emergency operation, TNM stage 
and perioperative blood transfusions. 
Our findings have not been verified in other studies, and the results should be interpreted with caution. 
Stratification according to location might be confounded by misinterpretation of the exact location. 
Tumours in these locations are rare, accounting for 15% of all CC, and our sample size is relatively 
53 
 
small. In addition, the level of significance was not very high (P=0.048), which imply a possibility of 
Type I error.  
Tumours of the splenic flexure have shown to be at high risk of obstruction, local recurrence and in-
hospital mortality190, 198, and a recent large study by Benedix showed that these tumours have the 
highest proportion of stage III-IV tumours and lymphatic invasion, which are factors associated with 
decreased survival274. 
We think that tumours in the area of the left flexure need special attention. It is advisable to perform a 
preoperative CT scan to detect possible advanced tumour growth, and the operation should be 
performed by highly competent colorectal surgeons.  
Perioperative blood transfusion (PBT): We found (Paper 1) an increased risk of death (HR 1.8, 
P=0.008) in patients who received three or more units of blood transfusion during the hospital stay, in 
accordance with the report from Edna et al.214, and in a study of younger patients operated for CC275, 
but contradicted in a large population based study from Spain212.  
Allogeneic blood transfusion is suggested to have negative immunologic effects on the host through 
increasing the number of suppressor T-lymphocytes and stimulating the production of a variety of 
antibodies. The activity of natural killer cells is depressed, and transfusion promotes the release of 
Prostaglandin E2, which inhibits interleukin-2 production and thus suppresses the immune response276. 
In animal models, PBT showed to enhance the growth of established metastases, but not of the 
primary tumour135. 
Patients who need PBT are anaemic for different reasons; more advanced cancer disease, increased 
comorbidity or greater loss of blood during surgery. It is reasonable to assume these factors to increase 
the risk of complications and poorer outcome. However, PBT was an independent risk factor in our 
study when adjusting for gender, age, emergency operation, stage and tumour location in multivariate 
analyses.   
In the review from Amato in 2006 (updated 2010), results from a meta-analysis of more than 12.000 
patients from 36 included studies, support the hypothesis that PBT have a negative effect on 
recurrence rate and survival277. This effect was observed regardless of timing or type of transfusion. 
The prognostic effect seemed to increase with the dose given, and was independent of preoperative 
anemia or preoperative blood loss.  
Our results support the evidence for a negative prognostic effect of PBT. Great effort should be 
undertaken to reduce perioperative bleeding and blood transfusion in CC patients.  
Erythropoietin given pre- or perioperative in order to reduce the need for transfusions has been 
evaluated, but so far, no evidence for the use of this medicament has been reported278.  
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Emergency operation: The present studies show an adverse impact of emergency operation on 
overall survival (Paper 1), postoperative mortality and complication rate (Paper 2) and on the risk for 
PC (Paper 4).  
Incidence 
Altogether, 25% of all admitted patients presented as emergencies (Paper 2), as compared to figures 
from 12%279 to 30%280 in other studies, possibly reflecting selection bias and differences in the 
definition of emergency presentation/operation. Such differences can also influence on reported 
outcomes. 
A total of 68% of the patients admitted as emergencies underwent surgical treatment. Among these, 
obstruction was present in 80%, and emergency operation was associated with more advanced stage 
and higher age, which has been shown in other studies280-282. The overall incidence of obstruction due 
to colon cancer varies from 7% to 34%, and has been reported to be more common in the left colon107, 
189, 194, 279, a finding not verified in our study.  
Perforation was present in 13% of emergency operated patients, and 5% were coecal perforations in 
patients with obstruction, in accordance with the study from McArdle et al. 193, but somewhat lower 
than in other reports 195, 281, 283, where only patients who undergo surgical treatment are included. 
The proportion of patients in need of emergency operation varied according to tumour location: 
- Coekum / ascending colon   15 % 
- Right flexure, transverse colon  24 % 
- Left flexure    30 % 
- Descending colon / sigmoid colon 21 % 
- Rectosigmoid flexure   16 % 
 
Surgical strategies in cases of left sided obstruction have been debated. In the present study, 
Hartmann’s procedure was associated with very high postoperative mortality and complication rates 
compared to one stage resection with primary anastomosis, in accordance with other studies284-288. This 
was probably caused by patient selection. Hartmann’s procedure is often recommended in high risk 
patients289, and this was the routine in our hospital. One randomized study concludes that there is no 
difference in morbidity or mortality between the two methods290. A review from 2007 of 29 studies 
including two RCT’s concluded that one-stage surgery appeared to be superior to two- or three stage 
procedures291. The item seems not to be settled. 
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Short term outcome 
Emergency surgery was associated with an increased risk of in-hospital mortality (OR 2.5, P= 0.001) 
and postoperative complications (OR 2.0, P< 0.001) after adjustment for tumour stage, age and 
gender. Similar findings have been presented from many other studies.   
Overall complication and mortality rates were not different in patients with obstruction and 
perforation, but the numbers were too small to draw firm conclusions. Other studies demonstrate 
higher postoperative mortality281, 282, 292 and morbidity281, 293 in patients with perforation.  
Long term outcome 
Emergency patients are older and probably frailer, and they present with disease at a more advanced 
stage, and the resection rate is lower than in elective patients (Paper 2). In addition, the postoperative 
mortality is increased, as discussed above.  All these factors contribute to reduced survival in 
emergency patients. Even in patients who underwent R0 resection and survived the primary operation, 
emergency operated patients had a 1.7 time increased risk of death within five years (Paper 1) 
Tumour perforation, spontaneously or inadvertently during surgery is associated with increased rates 
of local recurrence and reduced survival82, 294. Analyses of stage II patients from our cohort (not 
published) showed no difference in five year CSS, but reduced five year TTR in patients operated for 
perforation versus obstruction (Figure 8). However, no difference in recurrence rates, OS and CSS293 
or DFS263 was found between patients with perforation and obstruction in two smaller series. In a 
series of 83 patients with tumour associated perforation, patients with perforation proximal to the 
obstruction had higher operative mortality, but better cancer specific survival than patient with 
perforation at the tumour itself295  
Due to the poor prognosis, emergency operation should be avoided if possible. Reducing patient and 
doctor delay in symptomatic patients is important. In a recent Norwegian population based study the 
proportion of patients admitted with obstruction decreased over time296. Presentation at an earlier stage 
over time has been reported from Minnesota, USA201 and from Norway296. Screening programs may 
contribute to earlier diagnosis297, 298. 
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Figure 8: Time to recurrence following R0 resection, stage II (n=460) 
 
In patients with left sided colon obstruction the emergent problem can often be solved by intraluminal 
stenting as a ‘bridge to surgery’. Recent reports suggest that preoperative stenting of malignant 
obstruction followed by resection299, 300 or palliative chemotherapy101 is favourable.  Limitations of 
preoperative stenting are failure to place the stent, and the complication rates, especially perforation in 
the tumour area (see ‘General introduction’). Two recent multicentre RCT’s showed no decreased rate 
of stoma formation in patients treated with stent as bridge to surgery compared with emergency 
operation301. In one of the studies this was caused by a high rate of procedure related perforation, and 
of anastomotic leakage after resection in the bridge to surgery group302. The long term oncological 
outcome is also unclear. Consequently, more studies are needed to clarify the optimal treatment of 
obstructing colon cancer103, 303. At the moment, many authors recommend stenting in cases of left 
sided obstruction, especially in high-risk surgical patients304. 
Age: In the present studies, OS survival following resection with curative intent decreased with 
advancing age (Paper 1). However, RS related to age was not calculated, like in  the Norwegian 
national report showing lower RS in older patients202. These findings are also supported by a large 
regional study from Sweden that showed a decrease in CSS with increasing age305, and the results 
were similar when analysing stage II and III separately. Another large cohort study from USA272 
reported an increase in relative risk of 3.6% for every one-year increase in patient age. However, many 
studies find no independent impact of age on recurrence or survival in multivariate analyses138, 199, 234, 
263, 306 
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In our study, high age was associated with increased risk of postoperative complications (Paper 2), in 
accordance with other studies305, 307. Poorer short and long term outcome in elderly patients may partly 
be explained by a higher frequency of comorbidity, advanced tumour stage and emergency 
operation305. The latter was however not statistically significant in our study. In addition, older patients 
are less likely to receive adjuvant chemotherapy305.    
Gender: The age-adjusted incidence of colon cancer is higher in men than in women in Norway, but 
since women live longer than men, the actual number of cases is higher in women.  The present study 
(Paper 1) demonstrates no significant survival difference between genders following resection with 
curative intent, neither in overall nor in relative survival, in accordance with other reports138, 263.  
The exception was stage I patients; our study showed significantly better relative survival in females 
than in males, 101% (95% CI: 100-103) versus 80% (95% CI: 66-94).   
Chapuis reported better overall survival in females144, and Angell-Andersen202 reported lower cancer 
specific mortality in females with colorectal cancer. In a larger, multicentre series from Glasgow, 
comprising 2300 patients, five-year-OS and CSS following curative resection was better in women, 
when adjusted for age, site, presentation and stage308. Another study found better overall and disease 
free survival in females309. In contrast, a larger regional population based series from Sweden305 shows 
no difference in cancer specific survival among genders. 
In our study, postoperative mortality following major resection was not different between genders, but 
postoperative complication rate was higher among men than women (HR 1.6, P<0.01) (Paper 2), 
corresponding to findings from Sweden305.  
In the studies that show differences in outcome, it seems to be in favour of females. If there are any 
difference, a possible explanation may be that females have a stronger immune response following 
major abdominal surgery310. Some experimental observations show better posttraumatic immune 
competence in women than in men311-315, possibly due to genetic differences. Such differences might 
contribute to different outcome in CRC.  
 
Histopathological prognostic factors 
Number of lymph nodes: The number of harvested lymph nodes increased two-fold during the study, 
from a median of seven in the first to 15 in the last period (paper 5). The proportion of specimens in 
which at least 12 nodes were examined increased, and the proportion with examination of less than 
eight decreased.  
58 
 
Many factors determine how many lymph nodes are examined. Surgical factors are essential and both 
hospital caseload316, surgeon caseload88, 317 and surgeon specialisation318 influence on number of 
nodes. The importance of the surgical dissection is obvious and well documented79, 80, 134, 152. The 
standard surgical technique in our department has been central lymphovascular dissection with 
removal of all regional nodes including the apical nodes, corresponding to D3 dissection (see 
introduction), and the technique has probably not changed much during the study period. 
We found a variation from six nodes in specimens from the transverse colon to nine nodes in sigmoid 
specimens and 13 nodes in right hemicolectomy specimens (Table 6). This probably reflects the 
normal anatomical distribution of LN in the mesocolon, and not differences in surgical dissection. 
However, the low number found after transverse colon resection might also imply less radical surgery. 
Similar variations in the number of nodes according to type of resection have also been reported by 
others317, 319-321.   
 
Table 6: Lymph node harvest in relation to type of colonic resection (R0 resection) 
Resection type    N   No of lymph nodes 
          Median (range)   
 
Right hemicolectomy   423    13     (0–44) 
Resection of the transverse colon 18     6     (0–22) 
Left hemicolectomy   95    11    (0–36) 
Resection of the sigmoid   204     9     (0–43)   
 
Obviously, the quality of the pathological examination also has great influence on the number of 
lymph nodes detected and analysed. We observed improvement in the reporting of several other 
histopathological factors, like Crohn like lymphoid reaction and perineural invasion (seldom described 
in the first study period, reported in > 50 % in the later periods), and venous invasion (increased from 
7% to 88% during the study period).  This indicates an increased focus on high quality examination of 
CC specimens, including retrieval and examination of lymph nodes.  
There are several methods of specimen fixation122, 164, and the use of GEWF solution could improve 
detection of lymph nodes123 as suggested in our previously published study on the diagnostic value of 
SN concept121. The use of fat clearing techniques are often used in Japanese laboratories, probably 
improve the identification of LN. The level of pathologist specialisation might have significant 
influence on LN yield318, 322, 323, and the use of report templates has proven to increase the quality324. At 
our hospital, the Department of Pathology don’t use templates, but still have improved considerably 
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from 1993 to 2009. We think that improvement of the pathological examinations is the main reason 
for improved LN harvest.  
We found no influence of age on LN harvest, in contrast to other studies reporting lower numbers of 
LN in older patients147, 317. Some authors have suggested that a weaker immune response in older 
patients might explain a reduced lymph node harvest. A stronger immune response causes lymph node 
enlargement which makes them easier to detect.  
An adequate lymph node examination is necessary for correct staging of the disease. This was 
demonstrated in the present study; the increased LN harvest was followed by stage migration with 
reduced proportion of stage II and increased proportion of stage III patients. It is not likely that the 
true stage distribution changed during the study period, and this stage migration was therefore caused 
by better lymph node evaluation.  
How many nodes must be analysed in order to obtain correct staging? We observed stage migration 
when more than eight nodes were examined, but no migration when the group with 8–11 nodes was 
compared with the group with > 12 nodes. Stage migration was demonstrated when up to  13 LN were 
examined in a large national series from USA including more than 57.000 cases of T3N0-3 tumours151. 
A Canadian national series on more than 11.000 cases with pT3 tumours321 showed improved staging 
with increased number of examined nodes up to 5-7. Above this level, marginal effect on staging was 
seen with increasing number of nodes. The threshold value of minimal number of nodes to secure 
correct staging has been debated, varying from 6 to 20150-154. However, it seems logical that the 
minimal number should be related to tumour location319, due to the anatomic variations of LN in 
different  colonic segments.   
The present study also demonstrated that increased number of examined lymph nodes was associated 
with improved overall survival and time to recurrence in stage II cancers, which is in accord with other 
series89, 146. In stage III patients the results are conflicting88, 147, 149, 322, 325, and the number of examined 
lymph nodes had no significant prognostic impact on OS or TTR in the present series.   
Stage migration is often stated as the explanation for better outcome when more LN have been 
examined. Analysing more nodes decreases the risk of missing a positive node, and when false 
negative stage I/II patients are correctly diagnosed as stage III, the prognosis improves in both groups. 
This is referred to as Will Rogers phenomenon326 after the famous US comedian Will Rogers, who 
stated “when the okies left Oklahoma and moved to California, they raised the average intelligence 
level in both states.”  
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Generally speaking, the Will Rogers phenomenon is obtained when moving an element from one set to 
another set raises the average values of both sets. The effect will occur when both of these conditions 
are met: 
1) The prognosis of patients being moved is below average for the group (stage I/II).   
2) The prognosis of patients being moved is above the current average of the set it is entering 
(stage III).  
This phenomenon is thought to explain many observations of apparent improved outcome in 
epidemiological studies from a variety of biomedical fields, and is a type of information bias 
associated with better diagnostics. Changes in the criteria for assigning patients to the various stages of 
a disease can produce spurious improvements in stage-specific prognosis, even though the outcome of 
individual patients has not changed. In oncology, both improvements in the diagnosis of LN 
metastases and new imaging tools, which detects more distant metastases before they become evident 
clinically, can cause stage migration. Most likely it explains some of the improvement shown in stage 
I-III patients in the present study, which is in accordance with other reports148, 154, 327. In the large study 
from USA151, improved overall survival was observed when up to 25 LN were examined.  
In patients with a diminished immune response - an established negative prognostic factor136 - LN are 
more difficult to detect146. This might partly explain why patients with few nodes have an inferior 
prognosis.   
Other factors also have contributed to improved survival throughout the study periods. We found 
improved overall survival for all admitted patients, in accord with large national studies202, 230, 262. 
Several non-surgical and non-stage-migration factors may explain this, for instance better 
perioperative patient care. The use of adjuvant chemotherapy in stage III patients from 1997 might 
also have contributed.    
Lymph node ratio (LNR): The present study demonstrates a significant impact of LNR on OS and 
TTR in stage III patients (Paper 5) both in uni- and multivariate analyses, in accordance with other 
publications155, 158, 159, 328, 329. LNR remained a significant prognostic factor when adjusted for the total 
number of LN examined.                  
LNR decreases with increased number of negative nodes, and in our study, the proportion of patients 
with low LNR increased parallel to increased total number of LN due to equal median number of 
metastatic nodes was equal during the study period. One could assume that the number of metastatic 
nodes would increase when more nodes were examined. However, a low number of metastatic LN in 
upstaged patients would counteract this.  
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Stage III patients represent a heterogeneous group according to TNM classification (Table 2)64, 65. A 
low number of examined LN implies the risk of incorrect classification within stage III (N1a – 
N2b)157. In the present study, we found median two positive LN in stage III patients, and this number 
was independent of the total number of examined LN (1-7, 8-11 and >11). Regarding LNR, over-
staging happen when negative nodes are not discovered and under-staging if positive nodes are 
undiscovered. In the large series on stage III patients by Wang et al. (n > 24.000)157, a minimum of 14 
nodes are recommended to obtain correct staging, and thus a reliable LNR classification of the 
patients. This study concludes that LNR is a more accurate prognostic factor than the total number of 
examined nodes, in accordance with other reports158, 330 including a review comprising 12 studies on 
colon cancer160. The total number of examined LN seems to have less prognostic impact than LNR in 
stage III patients. However, LNR should not be regarded as a substitute for adequate LN dissection155.     
The prognostic impact of the total number of positive LN in stage III patients has been investigated, 
and the results are diverging; some report significant impact331, 332 whereas others does not156, 329, 333. 
Our study does not include corresponding analysis.  
LNR has been analysed as a continuous variable in a few studies showing significant impact on OS, 
CSS155 and DFS155, 159. Most studies analyse the prognostic impact of LNR by stratification into 
groups; we used quartiles of LNR, like other authors155, 160, 334. Additionally, some reclassify these 
categories based on maximal separation of the survival curves in univariate log rank analysis156, 332, 333. 
Others use categories based on literature (anticipated minimum number of LN required for accurate 
staging)157, 330, mean of LNR328 or classification and regression trees to determine high discriminating 
cut off points158. The threshold values for such LNR categories will differ due to differences in the 
total number of examined LN and the number of positive LN among study populations. Our data 
based on quartiles suggests that the optimal cut off value for prognostication was between the lowest 
(LNR < 0.11) and the three highest quartiles, similar to the results in the study by Lee et al.333. 
The interpretation of studies on prognostic impact of LNR is also difficult due to varying routines with 
regard to adjuvant chemotherapy. Some authors describe the use of chemotherapy clearly156, others do 
not157, and the chemotherapy regimens also vary155. These differences might have impact on the 
results, confounding the prognostic value of LNR. In the present study we adjusted for adjuvant 
chemotherapy in the multivariate analyses, but not for the two alternative regimens used, as the data 
were missing.    
To sum up, LNR is a promising indicator for prognostication of stage III patients. However, high 
quality surgery and pathology is mandatory for an adequate harvest and examination of lymph nodes, 
and consensus with regard to the method used to stratify patients into prognostic groups is necessary. 
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Micrometastases / Isolated tumour cells: Occult metastases (MM/ICT) was discovered in 31% of 
stage I-II colon cancer (paper 3), and was associated with reduces survival; in patients with and 
without MM/ITC, TTR was 75% and 93% (P=0.012), respectively. This population based, prospective 
study was made on the patient cohort investigated for staging accuracy of the sentinel node concept121. 
All lymph nodes in the 126 patients without ordinary lymph node metastases were examined with 
IHC, not only the sentinel nodes, and none of these patients received adjuvant chemotherapy, which is 
strength of the study. When comparing MM/ITC positive patients with stage III patients, no difference 
in survival was found. However, adjuvant chemotherapy was administrated to most stage III patients, 
which probably influenced on the results.   
The possible impact on prognosis of occult nodal metastases was postulated in the early nineties172, 173, 
and has since then been debated. Some studies using immunohistochemistry to detect occult 
metastases have demonstrated significant prognostic value of MM/ITC in stage I-II patients171, 177, 335, 
including a Norwegian retrospective study (reduced relative and cancer specific survival)169, whereas 
others have not133, 175, 184. 
There are several possible reasons for different results across studies: 
- Many studies are analysing both colon and rectal cancer, despite the differences in anatomy, 
surgical technique, complications, (neo) adjuvant treatment and subsequent outcome between 
these two cancers.  
- The definition of MM/ITC varies133, 175, 176, or is not clearly stated171, 177, 336. In some studies 
ITC is not included as occult metastases184, 
- The different use of adjuvant chemotherapy have impact on results, as MM/ITC positive 
patients who receive such treatment are excluded in some studies175, 177, 184, and included in 
others335-337.  
- Examination has been made on different tissue samples, some on formalin fixed and paraffin 
embedded tissue133, 176, and some on fresh (frozen) tissue177, 336  
- Studies use different endpoints of survival; Overall survival133, 177, relative survival169, cancer 
specific survival338 or disease free survival171, 335. The definitions of endpoints (event / censor) 
is often not clearly defined176, which make comparisons difficult, as discussed earlier in this 
chapter.  
We used the endpoint defined as TTR258, which includes only colon cancer related events. 
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Methods for identification of MM/ITC 
At present, two methods are used for identification of MM/ITC. Detection of MM/ITC with reverse 
transcriptase polymerase chain reaction (RT-PCR) was described as superior to IHC in a meta-analysis 
from 2006339, where IHC upstaged 21-39% of the patients versus 31-54% by RT-PCR. Another meta-
analysis reached the same conclusions340, but most series included are retrospective and small, which 
gives low statistical power341. In the multicentre trial of Bilchik (n=152)337, four IHC negative patients 
were upstaged by TR-PCR. The high sensitivity of RT-PCR is however associated with low 
specificity, giving risk of false positive results341-343. Still, most series using this technique shows 
significant prognostic impact of MM/ITC336, 338. In the present study, 31% of stage I-II patients proved 
to have occult nodal disease in accordance with other studies using IHC. This number might still be 
too low, and false negative cases might influence on our results.     
Median 12 nodes were examined in the present study, which implicate that about half of the patients 
had less than the minimum number of nodes recommended for accurate staging. The fraction of 
MM/ITC positive patients was equal when analysing patients with less than 12 and 12 or more nodes, 
indicating a correct staging of patients with lower number of examined LNs. Nevertheless, the 
possibility of under-staging cannot be ruled out. Seven per cent of the MM/ITC negative patients 
experienced recurrence, which may be a consequence of possible under-staging.  
Prediction of occult nodal disease has been investigated by Wasif et al.344, showing association with 
low differentiation, advanced T-stage ( pT3-4) and lymphovascular invasion in univariate analysis. 
These factors have adverse impact on prognosis. In the future, supplementary analyses to detect occult 
nodal disease could be an option in node negative patients with unfavourable characteristics of the 
primary tumour. 
Peritoneal carcinomatosis: The present study (Paper 4) demonstrates that 8.3% of all admitted 
patients had PC at time of diagnosis. Probably this number is underestimated, as some patients who 
were not operated or autopsied, could have undetected PC. CT of the abdomen was not routinely done 
until the last few years of the study. 
There are few reports on the true incidence of synchronous PC in unselected, prospective series. Some 
investigate both patients with synchronous and metachronous PC345, 346. The retrospective series from 
Jayne et al.347 report 7% PC at time of diagnosis, in according with our findings.  
Our study revealed some new and interesting findings. Firstly, there was a higher incidence of PC in 
tumours located in the right colon. One possible explanation for this could be the differences in 
tumour genetics39, 266, 268, 269 between right- and left-sided cancers, which could contribute do different 
patterns of spread. Other studies on the incidence of PC in relation to location of the primary tumour 
have not been presented until recently; one author reported higher incidence of PC among right sided 
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tumours (univariate analysis)348, and another showed higher rate of patients with multiple peritoneal 
metastases  in right sided tumours72. The study by Meguid272 showed poorer prognosis in right sided 
tumours, but association with PC was not analysed.  
Secondly, females had higher risk of PC than men, as demonstrated in both univariate and multivariate 
analyses. Gender related incidence is scarcely described in the literature. In a recent retrospective 
series from Japan of more than 2000 patients who all underwent surgery for colon or rectal cancer, 
there was no difference between genders72. The association between PC and female gender might be 
confounded by other, unknown factors, and has to be confirmed in future studies. 
Furthermore, our study showed that PC patients were younger than the others (median age 71 versus 
75 years, respectively). The corresponding figures for mean age was 69 and 73 years (P=0.002). Mean 
age was 59 years346 and 62 years345 in two selected, small series of patients with mix of synchronous 
and metachronous PC. A recent study of similar size as the present (Non-PC: n=975, PC: n=75), report 
that PC patients were significant younger than non-PC patients in univariate analysis348. Strength of 
our study is the inclusion of all patients with a diagnosis of colon cancer from a defined population, 
irrespective of the treatment given. The reason why PC is more frequent in younger patients might be 
that younger patients have tumours with more aggressive biology. 
Survival 
Median survival in PC patients was 9 months in the present study, slightly higher than other reports of 
median five to seven months345-347. Improved survival has been reported in patients with limited 
spread, treated with complete removal of all visible tumour tissue combined with intra-abdominal 
chemotherapy349.  The study by Pestieau350 showed median survival 24 months and five year survival 
(actuarial) of 30% in patients with complete cytoreduction. In the present study, none of the patients 
received HIPEC treatment, but several of them had palliative chemotherapy. 13 patients (14% of all 
patients with PC) had limited/single spread to the peritoneum, which could be removed radically, and 
survival in these patients was median 31 months. These figures correspond to the findings of 
Sadahiro348, who report median survival of 21 months in patients with limited PC and no LN 
involvement. The variations in survival illustrates a need of clear definitions of PC to make reliable  
comparisons of outcome analyses, and a focus should be held on patients with limited PC, who could 
be cured by surgery.  
TP53 mutations: Mutation in TP53 gene was significantly more frequent in patients with peritoneal 
carcinomatosis than in those without signs of PC. This finding is in accordance with another report271, 
and supported by association between TP53 gene products and PC351. However, when comparing 
TP53 mutation status in PC patients and non-PC patients with distant metastases in other locations, no 
difference was found. The mutation rate was approximately 50%, which correspond with figures from 
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other authors54, 56. This might indicate that TP53 mutations are associated with advanced disease rather 
than PC itself.  
The distribution of TP53 mutation types within exons five to eight compared with the literature is 
shown in Figure 9; both frequencies and types of mutation in PC patients are in accordance with 
multicentre non-PC patients261, and colorectal cancers in the IARC database352, supporting our 
findings. 
TP53 gene mutations are common in CRC, and known to be associated with both CIN tumours and 
distal location of the tumour (see ‘Introduction’). Association with tumour location was not found in 
our study, but in left sided cancers, mutation was more prevalent in men than in women. This is to our 
knowledge not reported earlier. 
A negative prognostic impact of TP53 mutations is reported in two meta-analyses comprising 68 
studies129, 353. Data from a large multicentre study indicate that the prognostic significance is dependent 
on both tumour location (proximal versus distal colon), and location of the mutations56.  
 
 
Figure 9: Schematic overview of codon distribution and type of TP53 mutations in exons 5 to 8. 
The upper panel shows the distribution of mutations in Aker patients with peritoneal carcinomatosis 
(PC), the panel in the middle is the multicentre non-PC patients and the lower panel is stage IV 
tumours from the multicentre non-PC patients (Paper 4). Hot-spot codons known from the literature to 
be mutated are indicated with codon number. 
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Conclusions 
 
The present studies have revealed an independent prognostic impact of several clinical and 
histopathological factors that formerly have been debated: 
- Tumour location in the splenic flexure and descending colon was associated with reduced 
survival due to low resection rates. Following major resection with curative intent, tumour 
location in the transverse colon, splenic flexure and descending colon was an independent 
negative prognostic factor.  
- In stage I/II patients, the presence of micrometastases or isolated tumour cells in the regional 
lymph nodes has a significant negative prognostic impact. The prognosis in patients with ITC 
is probably similar to patients with MM, and not much different from the prognosis in stage 
III patients.  
- In patients who underwent curative resection, the lymph node harvest increased during the 
study period. The most likely explanation is improvement of the pathological examination of 
the specimens. 
- Evaluation of more regional lymph nodes was associated with stage migration, with upstaging 
of stage I-II cancers to stage III 
- Evaluation of more lymph nodes was associated with improved survival in stage I-III patients. 
This is probably partly explained by stage migration and Will-Rogers phenomenon, an 
example of classification bias due to better diagnostics  
- Overall survival in all admitted patients improved during the study period, showing that other 
factors than stage migration contributed, and indicate a true improvement during the period 
- In stage III patients, LNR was a stronger prognostic factor than the total number of examined 
lymph nodes. Stage III patients with LNR < 0.11 have a favourable prognosis     
- Perioperative blood transfusion of three or more units had a negative prognostic impact 
The studies also revealed the novel findings that peritoneal carcinomatosis of colon cancer origin is 
most frequent in women, and in patients with tumour in the right colon. The PC patients are slightly 
younger than non-PC patients.  
Peritoneal carcinomatosis is independently associated with mutations in the TP53 tumour suppressor 
gene.   
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Other prognostic factors that were well established when our studies started, have been confirmed:   
Advancing TNM stage and R-stage, and emergency operation is associated with high postoperative 
mortality and complication rates and reduced long time survival. Hartmann’s procedure and surgical 
treatment without resection was associated with very high mortality, probably due to patient selection. 
Emergency operation should be avoided if possible. 
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Future studies / perspectives 
 
The list of well-established prognostic factors and of factors which probably have prognostic impact is 
long, including a variety of clinical, histopathological and molecular / genetic factors. Future studies 
are therefore demanding, because large studies are needed to define the effect of new factors while 
adjusting for other, known factors.   
Two new developments in surgical technique need further evaluation; the technique of complete 
mesocolic excision and the use of laparoscopic surgery. To evaluate outcome of these techniques, 
adjustment for prognostic variables is necessary. Great focus on improvement of the surgical 
technique is important, and specialised colorectal surgeons taking part in all operations, including 
emergency operations, should contribute to improve results.   
Future studies should ideally be population based to avoid selection bias; if not, comprehensive 
information on patient selection is obligatory. Analyses should be carried out based on consensus of 
endpoint definitions, which is mandatory for meaningful comparisons of results. Several hypotheses 
should be tested in randomized trials.   
Many of the findings in the present study may have impact on the clinical management of colon 
cancer patients, but need confirmation in future studies: 
- Most stage II patients do not receive adjuvant therapy, but some 20% - 30% will have a 
recurrence. Investigations with regard to MM/ITC seems to be a promising tool for 
identification of patients at high risk of recurrence, and who might gain benefit of adjuvant 
chemotherapy. A randomised controlled trial (RCT) would be necessary to test this.  
- About half of stage III patients are cured by surgery alone. A low lymph node ratio indicates a 
favourable prognosis. Patients with relative contra-indications to the use of AT who have a 
low LNR, should probably not be treated by AT. Fit patients with low LNR could enter a RCT 
to investigate a potential survival benefit of AT. The optimal cut-off value for a “low” LNR 
needs to be established. The potential prognostic value of MM/ITC in stage III patients with 
low LNR should be studied to identify patients with less favourable prognosis in this group.  
- Future studies of the prognostic impact of the total number of examined lymph nodes should 
be stratified according to subsites of the tumours, as recent data suggests that tumour 
properties and number of nodes varies with different locations. 
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High quality surgery and high quality pathological examination are preconditions for correct staging 
and correct interpretation of results from the studies proposed above.  
- Standardisation of methods used to identify MM/ITC would be an advantage. 
- There is still not agreement on how many lymph nodes must be examined for correct staging 
and optimal prognostication 
- Our finding of the prognostic impact of tumour location needs confirmation. The surgery for 
CC should be standardised; however, we think that tumours at certain ‘difficult’ locations (like 
the splenic flexure) need special attention.  
- Emergency operation is still a challenge, and should be avoided if possible. Earlier diagnosis 
through better public information and screening programs, and avoidance of patient and doctor 
delay, might contribute to reduce the number of emergency operations. The use of 
endoluminal stents for immediate decompression in obstructing cancer needs further 
evaluation.  
Extensive research is going on worldwide in order to investigate the prognostic and predictive value of 
biomolecular / genetic markers. We hope to contribute through our translational research program, 
including investigations of ploidy, microsatellite instability, protein markers, gene signatures and 
transcriptional profiling.   
In the future, staging of the patients should be based on more extensive systems based on clinical, 
histopathological and biomolecular markers with prognostic impact. A more exact prognostication is 
necessary for optimal treatment and follow up of the individual patient.  
Improvements in preoperative staging methods, the possible use of neo-adjuvant therapy to some 
patients, the use of more sophisticated prognostic tools and patient tailored treatment implies that the 
treatment of colon cancer patients will be a multidisciplinary task in the future.  
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